<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pathogens</journal-id><journal-id journal-id-type="iso-abbrev">Pathogens</journal-id><journal-id journal-id-type="pmc-domain-id">2622</journal-id><journal-id journal-id-type="pmc-domain">pathogens</journal-id><journal-id journal-id-type="publisher-id">pathogens</journal-id><journal-title-group><journal-title>Pathogens</journal-title></journal-title-group><issn pub-type="epub">2076-0817</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10745672</article-id><article-id pub-id-type="pmcid-ver">PMC10745672.1</article-id><article-id pub-id-type="pmcaid">10745672</article-id><article-id pub-id-type="pmcaiid">10745672</article-id><article-id pub-id-type="pmid">38133271</article-id><article-id pub-id-type="doi">10.3390/pathogens12121386</article-id><article-id pub-id-type="publisher-id">pathogens-12-01386</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Current Understanding of Bacillus Calmette-Gu&#233;rin-Mediated Trained Immunity and Its Perspectives for Controlling Intracellular Infections</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1045-2249</contrib-id><name name-style="western"><surname>de Araujo</surname><given-names initials="ACVSC">Ana Carolina V. S. C.</given-names></name><xref rid="af1-pathogens-12-01386" ref-type="aff">1</xref><xref rid="af2-pathogens-12-01386" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8956-7219</contrib-id><name name-style="western"><surname>Mambelli</surname><given-names initials="F">F&#225;bio</given-names></name><xref rid="af2-pathogens-12-01386" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sanches</surname><given-names initials="RO">Rodrigo O.</given-names></name><xref rid="af3-pathogens-12-01386" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6885-3438</contrib-id><name name-style="western"><surname>Marinho</surname><given-names initials="FV">F&#225;bio V.</given-names></name><xref rid="af3-pathogens-12-01386" ref-type="aff">3</xref><xref rid="fn1-pathogens-12-01386" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Oliveira</surname><given-names initials="SC">Sergio C.</given-names></name><xref rid="af2-pathogens-12-01386" ref-type="aff">2</xref><xref rid="af3-pathogens-12-01386" ref-type="aff">3</xref><xref rid="c1-pathogens-12-01386" ref-type="corresp">*</xref><xref rid="fn1-pathogens-12-01386" ref-type="author-notes">&#8224;</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Goletti</surname><given-names initials="D">Delia</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pathogens-12-01386"><label>1</label>Departamento de Gen&#233;tica, Ecologia e Evolu&#231;&#227;o, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil; <email>carolvalente97@gmail.com</email></aff><aff id="af2-pathogens-12-01386"><label>2</label>Departamento de Imunologia, Instituto de Ci&#234;ncias Biom&#233;dicas, Universidade de S&#227;o Paulo, S&#227;o Paulo 05508-900, SP, Brazil; <email>fabio_mambelli@yahoo.com.br</email></aff><aff id="af3-pathogens-12-01386"><label>3</label>Departamento de Bioqu&#237;mica e Imunologia, Instituto de Ci&#234;ncias Biol&#243;gicas, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil; <email>rcosanches@gmail.com</email> (R.O.S.); <email>fabiovitarelli@yahoo.com.br</email> (F.V.M.)</aff><author-notes><corresp id="c1-pathogens-12-01386"><label>*</label>Correspondence: <email>scozeus1@gmail.com</email></corresp><fn id="fn1-pathogens-12-01386"><label>&#8224;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>24</day><month>11</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2023</year></pub-date><volume>12</volume><issue>12</issue><issue-id pub-id-type="pmc-issue-id">451302</issue-id><elocation-id>1386</elocation-id><history><date date-type="received"><day>01</day><month>11</month><year>2023</year></date><date date-type="rev-recd"><day>20</day><month>11</month><year>2023</year></date><date date-type="accepted"><day>23</day><month>11</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>24</day><month>11</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>22</day><month>12</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-01-29 14:25:11.053"><day>29</day><month>01</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pathogens-12-01386.pdf"/><abstract><p>The bacillus Calmette&#8211;Gu&#233;rin (BCG) is an attenuated bacterium derived from virulent <italic toggle="yes">Mycobacterium bovis</italic>. It is the only licensed vaccine used for preventing severe forms of tuberculosis in children. Besides its specific effects against tuberculosis, BCG administration is also associated with beneficial non-specific effects (NSEs) following heterologous stimuli in humans and mice. The NSEs from BCG could be related to both adaptive and innate immune responses. The latter is also known as trained immunity (TI), a recently described biological feature of innate cells that enables functional improvement based on metabolic and epigenetic reprogramming. Currently, the mechanisms related to BCG-mediated TI are the focus of intense research, but many gaps are still in need of elucidation. This review discusses the present understanding of TI induced by BCG, exploring signaling pathways that are crucial to a trained phenotype in hematopoietic stem cells and monocytes/macrophages lineage. It focuses on BCG-mediated TI mechanisms, including the metabolic-epigenetic axis and the inflammasome pathway in these cells against intracellular pathogens. Moreover, this study explores the TI in different immune cell types, its ability to protect against various intracellular infections, and the integration of trained innate memory with adaptive memory to shape next-generation vaccines.</p></abstract><kwd-group><kwd>BCG</kwd><kwd>trained immunity</kwd><kwd>intracellular infections</kwd><kwd>innate memory</kwd></kwd-group><funding-group><award-group><funding-source>CNPq</funding-source><award-id>303044/2020-9</award-id></award-group><award-group><funding-source>FAPESP</funding-source><award-id>2017/24832-6</award-id><award-id>2023/02577-5</award-id><award-id>2023/03874-3</award-id></award-group><award-group><funding-source>Pro-Reitoria de Pesquisa-Universidade de S&#227;o Paulo</funding-source><award-id>Pro-Reitoria de Pesquisa USP</award-id></award-group><award-group><funding-source>National Institutes of Health</funding-source><award-id>R01 AI116453</award-id></award-group><funding-statement>This study was supported by grants funded by CNPq (grants 303044/2020-9), FAPESP (grants 2017/24832-6, 2023/02577-5, 2023/09226-3 and 2023/03874-3), Pro-Reitoria de Pesquisa-Universidade de S&#227;o Paulo (Pro-Reitoria de Pesquisa USP), and National Institutes of Health (NIH, grant R01 AI116453).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-pathogens-12-01386"><title>1. Introduction</title><p>The bacillus Calmette&#8211;Gu&#233;rin (BCG) vaccine, developed in the 1920s from virulent <italic toggle="yes">Mycobacterium bovis</italic>, has been administered for more than 100 years worldwide to protect children from severe forms of tuberculosis [<xref rid="B1-pathogens-12-01386" ref-type="bibr">1</xref>]. It is the only licensed vaccine for <italic toggle="yes">Mycobacterium tuberculosis</italic> (Mtb) control, given to around 100 million newborns annually [<xref rid="B2-pathogens-12-01386" ref-type="bibr">2</xref>,<xref rid="B3-pathogens-12-01386" ref-type="bibr">3</xref>]. Interestingly, the long-time usage of BCG in public health provided observations that drew attention to protective heterologous or non-specific effects (NSEs) [<xref rid="B4-pathogens-12-01386" ref-type="bibr">4</xref>,<xref rid="B5-pathogens-12-01386" ref-type="bibr">5</xref>]. For about 40 years, BCG has been the recommended intravesical immunotherapy for reducing the risk of tumor recurrence in patients with non-muscle invasive bladder cancer [<xref rid="B6-pathogens-12-01386" ref-type="bibr">6</xref>]. The BCG therapeutic potential has also been observed in the wart treatment arising from human papillomavirus (HPV) infection, in which patients revealed no recurrence among responders [<xref rid="B7-pathogens-12-01386" ref-type="bibr">7</xref>]. Moreover, epidemiological studies have shown that giving BCG to children is linked to an average decrease of 50% in infant mortality rates. This reduction is associated with an improvement in the initial immune response against sepsis, respiratory infections, and fever [<xref rid="B8-pathogens-12-01386" ref-type="bibr">8</xref>]. Other studies have conclusively shown that BCG revaccination significantly reduces the incidence of respiratory tract infections and pneumonia in both adolescents and the elderly [<xref rid="B9-pathogens-12-01386" ref-type="bibr">9</xref>,<xref rid="B10-pathogens-12-01386" ref-type="bibr">10</xref>]. Thus, evidence demonstrates that vaccinating humans with BCG can be beneficial against unrelated respiratory tract infections across a wide range of ages and can eliminate lesions, establishing a response similar to immunological memory and avoiding recurrence.</p><p>In essence, the BCG is a powerful tool in boosting the responsiveness of innate cells, particularly macrophages and dendritic cells (DCs), which function as antigen-presenting cells (APCs). The innate increased responsiveness leads to the activation of T cells and subsequent production of T helper cell type 1 (Th1) lymphocytes and interferon-gamma (IFN-&#947;) [<xref rid="B11-pathogens-12-01386" ref-type="bibr">11</xref>]. Overall, this inflammatory milieu contributes to an environment that favors cross-protection. Accordingly, the NSEs conferred by BCG against heterologous infections may originate from both innate and adaptive immunity responses. The heterologous adaptive immune response could occur by cross-reactivity (recognition of multiple antigens by T and B-memory cells) or bystander activation (activation of memory cells with weak or no costimulation by ongoing immune responses) [<xref rid="B12-pathogens-12-01386" ref-type="bibr">12</xref>]. Meanwhile, recent evidence emphasizes the importance of innate immune cells responding strongly during a subsequent, unrelated infection. Experiments using recombination activating gene <italic toggle="yes">1</italic> (RAG1) deficient or severe combined immunodeficiency (SCID) mouse strains (both lacking adaptive immune system) were of the utmost importance in this context [<xref rid="B13-pathogens-12-01386" ref-type="bibr">13</xref>,<xref rid="B14-pathogens-12-01386" ref-type="bibr">14</xref>,<xref rid="B15-pathogens-12-01386" ref-type="bibr">15</xref>,<xref rid="B16-pathogens-12-01386" ref-type="bibr">16</xref>], and encouraged further inquiries on how previous stimulation of innate immune cells could provide long-term cross-protection.</p><p>Deep research on the matter supported the conceptualization of a new innate immune system characteristic: trained immunity (TI). This term was coined by Netea et al. in 2011 and was well received by the scientific community in order to differentiate TI from the classical adaptive immune memory, historically referred to just as &#8220;immune memory&#8221; [<xref rid="B17-pathogens-12-01386" ref-type="bibr">17</xref>]. Among the key differences between TI and classical adaptive immune memory are (1) the maintenance of the memory status by epigenetic reprogramming instead of genetic rearrangement and selection of specific antigen receptors and (2) the lasting response provided by progenitor cells, mostly undifferentiated hematopoietic stem cells (HSCs), contrasting to immune experienced lymphocytes [<xref rid="B13-pathogens-12-01386" ref-type="bibr">13</xref>,<xref rid="B14-pathogens-12-01386" ref-type="bibr">14</xref>,<xref rid="B15-pathogens-12-01386" ref-type="bibr">15</xref>]. In summary, the TI is initiated by a primary stimulus that leads to epigenetic and metabolic reprogramming (induction phase). The organism or cells then return to their basal level after the initial stimulation is removed (resting phase). During a homologous or heterologous secondary challenge, an increased innate functional response is observed (trained response phase). [<xref rid="B18-pathogens-12-01386" ref-type="bibr">18</xref>,<xref rid="B19-pathogens-12-01386" ref-type="bibr">19</xref>,<xref rid="B20-pathogens-12-01386" ref-type="bibr">20</xref>]. The cross-protection provided by TI is one of its hallmarks.</p><p>The TI investigation exploiting BCG aroused defining important aspects in the field. For instance, the finding that HSCs can transmit the trained phenotype to derived innate cells was achieved using this vaccine as a TI-inducer [<xref rid="B15-pathogens-12-01386" ref-type="bibr">15</xref>]. This observation supports the presence of a sustained memory due to the transmission of epigenetic signatures from proliferative and long-lasting progenitors to effector cells [<xref rid="B15-pathogens-12-01386" ref-type="bibr">15</xref>,<xref rid="B21-pathogens-12-01386" ref-type="bibr">21</xref>]. Afterward, this scenario of HSC-protective imprinting was classified as central-trained immunity, differing from peripheral-trained immunity, which is observed in blood or tissue-resident cells (<xref rid="pathogens-12-01386-f001" ref-type="fig">Figure 1</xref>) [<xref rid="B22-pathogens-12-01386" ref-type="bibr">22</xref>]. In the following sections, this review discusses evidence showing the central and peripheral TI mechanisms across different immune cell types, NSEs-mediated by BCG (including TI and T-lymphocyte heterologous responses) against intracellular pathogens, and detailed perspectives of how these mechanisms could be applied in the vaccine technology.</p></sec><sec id="sec2-pathogens-12-01386"><title>2. The Mechanisms of BCG-Mediated Trained Immunity in Multipotent Progenitors and Monocytic Lineage</title><p>As mentioned above, the BCG can reprogram innate cells, leading to their improved activity against related or unrelated pathogens. Accordingly, it has been demonstrated that BCG intradermally inoculated results in functional alterations of peripheral blood immune cells [<xref rid="B23-pathogens-12-01386" ref-type="bibr">23</xref>,<xref rid="B24-pathogens-12-01386" ref-type="bibr">24</xref>]. It was shown later that lasting (months or even years) peripheral trained responses due to intradermal BCG vaccination must be sustained by transcriptomic alterations in HSCs [<xref rid="B25-pathogens-12-01386" ref-type="bibr">25</xref>]. Additionally, BCG-systemic administration induces the reprogramming of HSCs in the bone marrow (BM) [<xref rid="B15-pathogens-12-01386" ref-type="bibr">15</xref>]. In these scenarios, TI-related mechanisms are dependent on shifts in metabolic circuits and epigenetic reprogramming [<xref rid="B23-pathogens-12-01386" ref-type="bibr">23</xref>]. Hence, metabolic and epigenomic rewirings in TI underlie functional changes, preparing cells and organisms to cope more readily when later exposed to different pathogens.</p><p>The central BCG-mediated TI is associated with the expansion of HSCs and their commitment to the myeloid lineage in the BM microenvironment [<xref rid="B15-pathogens-12-01386" ref-type="bibr">15</xref>]. Epigenetic changes induced by BCG in HSCs are indirect, as this bacillus is not able to infect these cells [<xref rid="B15-pathogens-12-01386" ref-type="bibr">15</xref>,<xref rid="B26-pathogens-12-01386" ref-type="bibr">26</xref>]. The BCG training of multipotent progenitors in BM is marked by increased STAT1 transcriptional levels, linked to a key role for IFN-&#947; since IFN-&#947; receptor (IFNGR)-deficient BM does not present expansion of HSCs upon intravenous (i.v.) BCG stimulation (<xref rid="pathogens-12-01386-f001" ref-type="fig">Figure 1</xref>) [<xref rid="B15-pathogens-12-01386" ref-type="bibr">15</xref>]. Although IFN-&#947; seems to be critical in inducing BCG-mediated TI, it is not limited to it, as the full landscape of immune responses in BM needs to be assessed. This reasoning is well explained by a recent study by Khan et al., 2020, in which they show BM stimulation with Mtb leads to the activation of immune pathways resembling those induced by BCG, such as STAT1 and IFN-&#947; signaling. However, Mtb also strongly induces the type I IFN pathway, dysregulates iron metabolism, and depolarizes mitochondrial-membrane potential in a region of difference (RD-1) dependent manner. This scenario compromises myelopoiesis, resulting in the death of these cells by receptor-interacting protein kinase 3 (RIPK3)-induced necroptosis and triggers susceptibility to further challenges with Mtb. Meanwhile, immunization with &#946;-glucan (another well-known TI-inducer) results in myelopoiesis induction in BM dependent on IL-1 pathway activation [<xref rid="B27-pathogens-12-01386" ref-type="bibr">27</xref>]. Thus, commitment to the myeloid lineage is a trait of the HSC-training process in BM, possibly induced by attenuated bacteria and pathogen-associated molecular patterns (PAMPs). Concordantly, the transfer of BCG-trained BM to immune-depleted mice confers greater antimicrobial control against heterologous infections compared to mice receiving na&#239;ve BM. It is feasible as trained effector cells will be derived from HSCs. These cells will inherit the epigenetic marks and migrate to the periphery during a heterologous infection (<xref rid="pathogens-12-01386-f001" ref-type="fig">Figure 1</xref>). Hence, differentiated cells may show increased inflammatory responses in infected tissues [<xref rid="B15-pathogens-12-01386" ref-type="bibr">15</xref>,<xref rid="B16-pathogens-12-01386" ref-type="bibr">16</xref>].</p><p>The lower disease rate due to BCG vaccination has been associated with the H3K27ac enrichment (a histone marker observed in active promoters and enhancers) in regulatory regions of inflammatory cytokines in peripheral blood mononuclear cells (PBMCs) [<xref rid="B10-pathogens-12-01386" ref-type="bibr">10</xref>]. Accordingly, another study demonstrated that human peripheral blood monocytes, 30 days post-BCG vaccination, exhibited H3K27ac enrichment in several regions associated with the inflammatory response, highlighting the genes related to the PI3K/Akt pathway [<xref rid="B23-pathogens-12-01386" ref-type="bibr">23</xref>]. Furthermore, greater Akt/mTORC1/S6K pathway activation was observed in BCG-trained monocytes in vitro, being the mTOR phosphorylation required for a metabolic change characterized by increased glycolysis and glutamine pathway. Akt/mTORC1-pathway inhibition abrogated the H3K4me3 enrichment (a marker of activated regulatory regions) and the H3K27me3 reduction (a marker of inactivated regulatory regions) in promoter regions of inflammatory cytokines, such as IL-6 and tumor necrosis factor &#945; (TNF-&#945;) [<xref rid="B20-pathogens-12-01386" ref-type="bibr">20</xref>]. Given the above, the Akt/mTORC1-axis enhancement is a hallmark of BCG-trained monocytes, driving metabolic, epigenetic, and functional remodeling in these cells, which are integrated into an interdependent circuit (<xref rid="pathogens-12-01386-f002" ref-type="fig">Figure 2</xref>). Additionally, a straight association between metabolism and epigenome was elucidated by the contribution of the glutamine pathway to chromatin modifications [<xref rid="B20-pathogens-12-01386" ref-type="bibr">20</xref>]. The glutamine pathway is responsible for metabolite accumulation in the tricarboxylic-acid (TCA) cycle, such as fumarate and citrate. These metabolites, after being transported from mitochondria to the cytoplasm, interfere with the histone-modifying enzymes [<xref rid="B20-pathogens-12-01386" ref-type="bibr">20</xref>,<xref rid="B28-pathogens-12-01386" ref-type="bibr">28</xref>].</p><p>Both BCG-trained human-circulating monocytes and mouse BM-derived macrophages (BMDMs) have a potentialized capacity to control pathogens, namely viruses, bacteria, protozoa, and fungi. The BCG-trained responses elicited by these cells are associated with higher control of Mtb, <italic toggle="yes">Brucella abortus</italic>, <italic toggle="yes">Candida albicans</italic>, <italic toggle="yes">Leishmania braziliensis</italic>, influenza A virus (IAV), yellow fever virus (YFV), and others [<xref rid="B15-pathogens-12-01386" ref-type="bibr">15</xref>,<xref rid="B16-pathogens-12-01386" ref-type="bibr">16</xref>,<xref rid="B23-pathogens-12-01386" ref-type="bibr">23</xref>,<xref rid="B29-pathogens-12-01386" ref-type="bibr">29</xref>,<xref rid="B30-pathogens-12-01386" ref-type="bibr">30</xref>]. These BCG-trained phagocytes present an increased expression of costimulatory molecules and secrete high levels of inflammatory cytokines, such as IL-6, TNF-&#945;, IL-12, and IL-1&#946; in response to unrelated stimulation (<xref rid="pathogens-12-01386-f002" ref-type="fig">Figure 2</xref>) [<xref rid="B16-pathogens-12-01386" ref-type="bibr">16</xref>,<xref rid="B20-pathogens-12-01386" ref-type="bibr">20</xref>]. The improved ability to produce IL-1&#946; appears to be a predictive factor of protection in BCG-mediated TI. For instance, trained human monocytes producing higher IL-1&#946; amounts correlated with lower YFV viremia. Furthermore, genetic polymorphisms in the IL-1&#946; promoter, IL-1 or IL-18 receptor coding gene, and inflammasome components, such as apoptosis-associated speck-like protein containing a CARD (PYCARD/ASC), are shown to affect the magnitude of BCG-trained responses, leading to lower production of other inflammatory mediators [<xref rid="B23-pathogens-12-01386" ref-type="bibr">23</xref>]. This evidence is supported by recent findings from our group, which demonstrated that canonical and caspase-11-mediated-non-canonical inflammasome pathways were enriched in BCG-trained BMDMs against <italic toggle="yes">B. abortus</italic> infection. The IL-1&#946; release occurred along with the expressive caspase-1 processing, higher pro-IL-1&#946;, caspase-11, NLRP3 expression, and GSDMD cleavage (<xref rid="pathogens-12-01386-f002" ref-type="fig">Figure 2</xref>) [<xref rid="B16-pathogens-12-01386" ref-type="bibr">16</xref>]. Therefore, the IL-1 pathway plays a pivotal role in BCG-mediated TI, being by itself an inflammatory pathway associated with protection against viral and bacterial infections [<xref rid="B16-pathogens-12-01386" ref-type="bibr">16</xref>,<xref rid="B23-pathogens-12-01386" ref-type="bibr">23</xref>]. Certainly, higher NLRP3 expression by BCG-trained macrophages suggests the importance of this receptor in the TI establishment. Additionally, NLRP3&#8217;s role may be related to the mTORC1-complex activity, as both contribute to macrophage polarization towards the type 1 (M1) profile [<xref rid="B31-pathogens-12-01386" ref-type="bibr">31</xref>,<xref rid="B32-pathogens-12-01386" ref-type="bibr">32</xref>,<xref rid="B33-pathogens-12-01386" ref-type="bibr">33</xref>].</p></sec><sec id="sec3-pathogens-12-01386"><title>3. Trained Immunity Mechanisms in Neutrophils and Dendritic Cells (DCs)</title><p>Although most of the evidence linked to TI is demonstrated in macrophages and natural killer (NK) cells (subject well detailed in&#8212;[<xref rid="B34-pathogens-12-01386" ref-type="bibr">34</xref>,<xref rid="B35-pathogens-12-01386" ref-type="bibr">35</xref>,<xref rid="B36-pathogens-12-01386" ref-type="bibr">36</xref>]), BCG vaccination also induces the elevated functional capacity of peripheral blood neutrophils. Following 90 days post-vaccination with this bacillus, human-circulating neutrophils showed H3K4me3 enrichment in promoter regions of inflammatory cytokines (IL-1&#946; and IL-8), mTOR, and phosphofructokinase (PFK, an enzyme that belongs to the glycolytic pathway). Despite presenting H3K4me3-enriched regulatory regions, chromatin accessibility did not reflect increased gene transcription compared to baseline. This finding suggests that neutrophils remain with more accessible gene regions, even though immune effector production only occurs upon a secondary stimulation [<xref rid="B24-pathogens-12-01386" ref-type="bibr">24</xref>]. This characteristic is similar to that previously observed in BCG-trained monocytes [<xref rid="B23-pathogens-12-01386" ref-type="bibr">23</xref>]. An exception to the immune effector production pattern was observed by higher PI3K/Akt-pathway expression upon BCG vaccination, indicating its crucial role in neutrophil training as well. Following in vitro secondary Mtb or <italic toggle="yes">C. albicans</italic> challenge, BCG-trained human neutrophils expressed an increased amount of activation markers, such as CD11b, and a lower quantity of programmed death-ligand 1 (PD-L1, a checkpoint protein associated with immunosuppression). Moreover, these trained cells presented superior degranulation capacity and increased production of reactive oxygen species (ROS), elastase, and lactate accompanied by elevated killing capacity against <italic toggle="yes">C. albicans</italic>, although neutrophil extracellular traps (NETs) production has not changed [<xref rid="B24-pathogens-12-01386" ref-type="bibr">24</xref>]. Therefore, BCG-trained neutrophils exhibited functional reprogramming based on epigenetic and metabolic changes, readily controlling the growth of heterologous pathogens through enhanced antimicrobial functions.</p><p>It is worth mentioning that BCG training in DCs has not been demonstrated so far. Nevertheless, the memory-development capacity of DCs has been reported following intranasal immunization of mice with an experimental strain of <italic toggle="yes">C. neoformans</italic> capable of producing IFN-&#947; (H99&#947;) [<xref rid="B37-pathogens-12-01386" ref-type="bibr">37</xref>]. DCs isolated from their lungs displayed increased transcriptional levels of IFN-&#947;, STAT1, IL-12, and nitric oxide synthase 2 (NOS2). Intriguingly, after 70 days of H99&#947; immunization, increased inflammatory-cytokine production by DCs from H99-&#947;-vaccinated mice was observed specifically against the <italic toggle="yes">C. neoformans</italic> challenge. Following <italic toggle="yes">lipopolysaccharide</italic> (LPS), <italic toggle="yes">S. aureus</italic>, and <italic toggle="yes">C. albicans</italic> exposure, these cells did not produce superior amounts of cytokines compared to controls. This evidence demonstrates a unique feature of training exhibited by DCs, suggesting a pathogen-specific response [<xref rid="B37-pathogens-12-01386" ref-type="bibr">37</xref>]. Another study, controversially, demonstrated that even upon exposure to immunomodulatory stimuli, such as IL-4, a type 1 DC profile induced by synergistic stimulation with IFN-&#947; and TNF-&#945; in vitro was stable and resistant to switching to a type 2 DC profile [<xref rid="B38-pathogens-12-01386" ref-type="bibr">38</xref>]. H3K4me3 enrichment in promoter regions of inflammatory genes, like <italic toggle="yes">Il12b</italic> and <italic toggle="yes">Nos2</italic>, was also observed in the model. Moreover, the mixed lineage leukemia 1 (MLL1) methyltransferase enzyme mediated these epigenetic changes, and the presence of TNF-&#945; was essential for stabilizing the inflammatory profile in DCs and their myeloid precursors [<xref rid="B38-pathogens-12-01386" ref-type="bibr">38</xref>]. These findings suggest broad applicability in the context of pathogens that possess immunomodulatory PAMPs responsible for impairing Th1 responses. Thus, whether DC-trained responses are pathogen-specific or broad-spectrum remains a point yet to be investigated. Moreover, whether BCG can induce TI in DCs against heterologous infections is still an open question.</p></sec><sec id="sec4-pathogens-12-01386"><title>4. Crosstalk between Trained Innate Immune Cells and Lymphocytes</title><p>It is supposed that the TI exhibited by innate cells interferes with adaptive immunity activity and vice versa. A piece of evidence is that the adoptive transfer of IFN-&#947;+TNF-&#945;-trained DCs to TNF-&#945; deficient mice previously infected with <italic toggle="yes">C. neoformans</italic> significantly raised the quantity of IFN-&#947;-producing T CD4<sup>+</sup> lymphocytes while reducing the number of IL-5-producing CD4<sup>+</sup> T lymphocytes [<xref rid="B38-pathogens-12-01386" ref-type="bibr">38</xref>]. Moreover, it is plausible that the increased production of inflammatory cytokines by BCG-trained macrophages, such as IL-12 and TNF-&#945;, contributes to an environment that favors Th1 response establishment. Another example, demonstrated by our team and others, is that BCG-trained macrophages presented increased MHC-II receptor and costimulatory molecule expressions on the cell surface upon secondary challenge [<xref rid="B16-pathogens-12-01386" ref-type="bibr">16</xref>,<xref rid="B39-pathogens-12-01386" ref-type="bibr">39</xref>]. On a two-way street, BCG-trained macrophages can better control bacterial growth upon IFN-&#947;-exogenous stimulation compared to untrained macrophages. Accordingly, antimicrobial mechanisms exerted by macrophages, such as nitric oxide (NO) production, were enhanced in BCG-trained macrophages [<xref rid="B16-pathogens-12-01386" ref-type="bibr">16</xref>]. Even though the IFN-&#947; source can be from innate and adaptive immune systems, it is reasonable that IFN-&#947; produced by lymphocytes contributes to an increment in TI-effector functions. Further, recent studies have shown that neutrophils play an important role in the neighboring cells, including lymphocytes and macrophages [<xref rid="B40-pathogens-12-01386" ref-type="bibr">40</xref>,<xref rid="B41-pathogens-12-01386" ref-type="bibr">41</xref>]. Neutrophils may take part in inducing innate memory in macrophages. Chen et al., 2014, demonstrated that neutrophil depletion abrogated secondary protective responses exhibited by lung macrophages, which presented an elevated capacity to bind and kill pathogens [<xref rid="B42-pathogens-12-01386" ref-type="bibr">42</xref>]. Lastly, IFN-&#947; producing CD8<sup>+</sup> T lymphocytes are indispensable for training alveolar macrophage in the airways [<xref rid="B39-pathogens-12-01386" ref-type="bibr">39</xref>]. It is still necessary to clarify which cellular interactions are essential in establishing TI and trained responses during heterologous infections. This premise must be considered for central and peripheral TI.</p></sec><sec id="sec5-pathogens-12-01386"><title>5. The BCG NSEs against Intracellular Pathogens Comprise TI and Heterologous T cell Responses</title><p>The BCG administration in infants results in a lower mortality rate during the first month after immunization, which is associated with protection against neonatal sepsis and respiratory infections [<xref rid="B8-pathogens-12-01386" ref-type="bibr">8</xref>,<xref rid="B43-pathogens-12-01386" ref-type="bibr">43</xref>]. Furthermore, BCG revaccination in the elderly leads to a reduction in the incidence of unrelated respiratory infections, mainly viral ones [<xref rid="B10-pathogens-12-01386" ref-type="bibr">10</xref>]. These NSEs have been associated with two main immunological mechanisms: TI and heterologous T cell immunity [<xref rid="B44-pathogens-12-01386" ref-type="bibr">44</xref>]. Kleinnijenhuis et al., 2013, by immunizing volunteers with BCG, identified the activation of both mechanisms. In this regard, cytokine production, resulting from stimulation of PBMCs with mycobacteria and unrelated pathogens, was evaluated up to one year after BCG immunization. Long-term effects were associated with heterologous Th1 and Th17 responses based on IFN-&#947;, IL-17, and IL-22 production one year post-immunization. Otherwise, the short-term effects were associated with TI up to three months after immunization, considering TNF-&#945; and IL-1&#946; production. Additionally, receptors of the innate immune response also had increased expression in monocytes, up to one year after BCG initial stimulus [<xref rid="B45-pathogens-12-01386" ref-type="bibr">45</xref>]. In another interesting study, Arts et al., 2018, used vaccination with the YFV as a heterologous infection model (as exemplified previously in <xref rid="sec2-pathogens-12-01386" ref-type="sec">Section 2</xref>). This is a suitable approach for investigating NSEs since viruses are detected in the circulation after vaccination, and changes in viremia would be essential to attest to the heterologous protection induced by BCG. Indeed, immunization with BCG 28 days before the YFV challenge resulted in a significant reduction in viremia. Moreover, functional alterations were evidenced by a significant increase in IL-1&#946; and IL-6 production by PBMCs stimulated with LPS, Mtb, and <italic toggle="yes">C. albicans</italic>. Altogether, these findings experimentally certify the NSEs from BCG in humans [<xref rid="B23-pathogens-12-01386" ref-type="bibr">23</xref>].</p><p>Other studies demonstrated that BCG immunization promotes, in different mouse strains, significant protection against viral infections. They reported NSEs from BCG upon infection by IAV [<xref rid="B46-pathogens-12-01386" ref-type="bibr">46</xref>], Ectromelia virus [<xref rid="B47-pathogens-12-01386" ref-type="bibr">47</xref>,<xref rid="B48-pathogens-12-01386" ref-type="bibr">48</xref>], encephalomyocarditis virus [<xref rid="B49-pathogens-12-01386" ref-type="bibr">49</xref>,<xref rid="B50-pathogens-12-01386" ref-type="bibr">50</xref>], vaccinia virus (VV) [<xref rid="B51-pathogens-12-01386" ref-type="bibr">51</xref>], and others [<xref rid="B52-pathogens-12-01386" ref-type="bibr">52</xref>]. The protection conferred by BCG against encephalomyocarditis virus infection was correlated with macrophages in a lymphocyte-independent manner [<xref rid="B49-pathogens-12-01386" ref-type="bibr">49</xref>,<xref rid="B50-pathogens-12-01386" ref-type="bibr">50</xref>]. On the other hand, Mathurin et al., 2009, demonstrated that C57BL/6 mice showed resistance to VV when challenged 28 weeks after BCG immunization. The protective mechanism, however, does not appear to be related to TI but to the action of CD4<sup>+</sup> T cells and IFN-&#947;. Notably, animals were subjected to antibiotic clearance before the challenge in this model [<xref rid="B51-pathogens-12-01386" ref-type="bibr">51</xref>].</p><p>Since the COVID-19 pandemic emerged, the use of BCG has been extensively discussed concerning SARS-CoV-2 infection [<xref rid="B53-pathogens-12-01386" ref-type="bibr">53</xref>,<xref rid="B54-pathogens-12-01386" ref-type="bibr">54</xref>]. At first, ecological studies raised the hypothesis that countries containing current national BCG vaccination policies for all demonstrate a lower incidence of mortality from COVID-19 [<xref rid="B52-pathogens-12-01386" ref-type="bibr">52</xref>]. Since then, several studies have explored the protective role of BCG immunization against COVID-19. Recently published studies bring contrasting findings on this issue. Kaufmann et al., 2022, reported that K18-hACE2 mice or Syrian golden hamsters that received BCG i.v. were as susceptible as the unvaccinated group to intranasal (i.n) or intratracheal (i.t) infection with SARS-CoV-2/SB2 (B.4 lineage) [<xref rid="B29-pathogens-12-01386" ref-type="bibr">29</xref>]. In turn, other studies demonstrated a different outcome [<xref rid="B55-pathogens-12-01386" ref-type="bibr">55</xref>,<xref rid="B56-pathogens-12-01386" ref-type="bibr">56</xref>]. Zhang et al., 2022, showed that i.v. BCG immunization of K18-hACE2 mice promotes a decrease in the pulmonary and upper airway viral load following i.n infection with WT SARS-CoV-2 [<xref rid="B55-pathogens-12-01386" ref-type="bibr">55</xref>]. High HSC proliferation in the BM, along with greater differentiation into myeloid cells and consequent enrichment of macrophages and DCs, supported TI. Furthermore, metabolic evaluation of plasma and PBMCs revealed greater activation of the glycolytic pathway in vaccinated animals [<xref rid="B55-pathogens-12-01386" ref-type="bibr">55</xref>]. Singh et al., 2022, demonstrated that i.v. BCG immunization in the Syrian golden hamster model elicited protection with reduced lung viral loads and bronchopneumonia. Single-cell transcriptome profiling demonstrated higher recruitment of plasma cells, Th1, Th17, regulatory T cells (Treg), cytotoxic T lymphocytes (CTLs), and memory T cells to the lungs of BCG-immunized mice. These findings were observed together with a transcriptional shift towards antigen presentation and tissue repair [<xref rid="B56-pathogens-12-01386" ref-type="bibr">56</xref>].</p><p>Additionally, Hilligan et al., 2020, reported BCG-mediated protection, when mice were i.v. immunized. Reduced viral loads, ameliorated lung pathology, and decreased cytokine production and inflammatory cell recruitment were observed in the model [<xref rid="B57-pathogens-12-01386" ref-type="bibr">57</xref>]. However, when mice were immunized subcutaneously (s.c.) with BCG, protection was not achieved. Finally, another study used a non-human primate model [<xref rid="B58-pathogens-12-01386" ref-type="bibr">58</xref>] where rhesus macaques were immunized with BCG by aerosol administration. Despite the quick induction of monocytes and &#947;&#948;-T cells, overall protection was not achieved. As i.v. BCG immunization leads to direct engagement of the BM compartment (opposing local administration); one could suggest that TI induced in immune cell progenitors could account for stronger effects against viral challenge [<xref rid="B54-pathogens-12-01386" ref-type="bibr">54</xref>,<xref rid="B59-pathogens-12-01386" ref-type="bibr">59</xref>]. However, the mechanisms behind BCG i.v. immunization leading or not to protection against SARS-CoV-2 infection in the animal model still requires further elucidation.</p><p>As a parallel inquiry, several randomized trials are being conducted worldwide to evaluate whether BCG immunization is protective against COVID-19, but recent reports are still heterogeneous and not conclusive [<xref rid="B54-pathogens-12-01386" ref-type="bibr">54</xref>,<xref rid="B59-pathogens-12-01386" ref-type="bibr">59</xref>]. The trials, in general, evaluate the susceptibility and mortality against COVID-19 in countries in which neonatal BCG is a clinical practice and when adults are revaccinated with BCG. Here, several aspects could account for the reported heterogeneous observations. Firstly, immunological differences might be observed from BCG immunization of pre-vaccinated against BCG-na&#239;ve individuals. Secondly, the TI effects are expected to last up to 1&#8211;2 years [<xref rid="B59-pathogens-12-01386" ref-type="bibr">59</xref>], but additional influences should be studied throughout the lifespan. Also, susceptibility to infection should differ from healthcare workers to elders, from individuals with different genetic and environmental backgrounds, and also from individuals with comorbidities. All in all, despite these results raising several discussions, further investigation, such as broad meta-analyses, is required to establish a firm conclusion regarding BCG protection against COVID-19.</p><p>The NSEs mediated by BCG have also been reported against challenges by pathogens such as fungi and protozoa. SCID mice immunized with BCG and infected with <italic toggle="yes">C. albicans</italic> 2 weeks later presented a higher survival rate when compared to those immunized with PBS. This observation was accompanied by a reduction in the fungal burden in the kidneys. Furthermore, the same immunization-infection regimen generated splenic monocytes with greater capacity to produce TNF-&#945; when stimulated with LPS [<xref rid="B14-pathogens-12-01386" ref-type="bibr">14</xref>]. The deficiency in T and B cells suggested the TI action as the protective mechanism in this context. This was reinforced by the observation that such protection is partially dependent on NK cells, which, in addition, produced higher IL-1&#946; levels when stimulated by unrelated pathogens [<xref rid="B60-pathogens-12-01386" ref-type="bibr">60</xref>]. Concerning protozoa, Silva et al., 2021, demonstrated the relevant impacts of BCG in infections by different species of <italic toggle="yes">Leishmania</italic> spp. in vitro and in vivo. Training of human monocytes was performed with BCG for 24 h, followed by 5 days of resting and infection on the 6th day. The findings showed a significant reduction in the infection index of <italic toggle="yes">L. braziliensis</italic> and <italic toggle="yes">L. infantum</italic>. Additionally, mouse infection following 7 days of BCG i.v. administration promoted decreased <italic toggle="yes">L. braziliensis</italic> load in paw lesions and less <italic toggle="yes">L. amazonensis</italic> or <italic toggle="yes">L. infantum</italic> dissemination to organs such as the spleen and liver. The NSEs from BCG were mainly associated with the production of IL-32 [<xref rid="B61-pathogens-12-01386" ref-type="bibr">61</xref>]. BCG vaccination also affected the infection of another protozoan, <italic toggle="yes">Plasmodium yoelii</italic> (PyNL). Prior contact with BCG in this context promoted increased expression of antimicrobial molecules such as lactoferrin and cathelicidin, which were then associated with lower parasitemia observed in the animals [<xref rid="B62-pathogens-12-01386" ref-type="bibr">62</xref>].</p><p>Regarding the NSEs from BCG in bacterial infections, a recent study demonstrated that C57BL/6 animals immunized s.c. with BCG are protected against infection by <italic toggle="yes">S. pneumoniae</italic>. In addition to greater survival, animals had lower bacterial load in the lungs and spleen. Similar behavior was evidenced even when the infection was performed 16 weeks post-immunization. The observed protective phenotype was clearly related to the action of neutrophils and a possible contribution of alveolar macrophages [<xref rid="B63-pathogens-12-01386" ref-type="bibr">63</xref>]. Applying an experimental design slightly different, Mata et al., 2021, reported a heterologous protective effect against <italic toggle="yes">S. pneumoniae</italic>. However, in this approach, the protection and the reduced pathogen spreading were observed only due to BCG immunization by i.v. route [<xref rid="B64-pathogens-12-01386" ref-type="bibr">64</xref>]. Lastly, a study recently conducted by our team showed protective responses against <italic toggle="yes">B. abortus</italic> infection elicited 10 weeks after i.v. BCG immunization. We demonstrated that BMDMs presented a greater capacity to control intracellular bacterial replication along with potentiated production of inflammatory cytokines and metabolic rewiring. Importantly, we applied an antibiotic treatment following 4 weeks of BCG i.v. immunization, assuring that increased responses were mediated by TI and not due to concurrent stimulation. The reduction in the <italic toggle="yes">B. abortus</italic> burden in the spleen of C57BL/6 RAG<sup>&#8722;/&#8722;</sup> mice also confirmed that the protection was associated with enhanced innate immune responses [<xref rid="B16-pathogens-12-01386" ref-type="bibr">16</xref>]. Given the above, it is clear that the NSEs from BCG have been consolidated over the decades, even though the TI-related mechanisms underlying such effects are still under elucidation. This clarification can be applied to the improvement of health policies, such as the development of vaccine strategies that take into account TI.</p></sec><sec id="sec6-pathogens-12-01386"><title>6. Trained-Immunity-Based Vaccines (TIbVs) and What It Adds to the Field of Vaccinology</title><p>Vaccines, as we know (i.e., conventional vaccines), are designed to evoke adaptive immune responses against a specific pathogen and promote long-lasting immune memory (<xref rid="pathogens-12-01386-f003" ref-type="fig">Figure 3</xref>A). They are formulated to contain dead or attenuated pathogens, or even their subunits&#8212;purified or encoded by nucleic acids. B and T cell-specific responses will be orchestrated, and long-term protection will be marked by the persistence of circulating antibodies and immune memory cells, leading to reactivation upon new pathogen exposure [<xref rid="B65-pathogens-12-01386" ref-type="bibr">65</xref>]. However, pronounced immune responses might need immunizations containing adjuvants in their formulations for proper DC activation, especially for subunit and nucleic acid vaccines [<xref rid="B66-pathogens-12-01386" ref-type="bibr">66</xref>]. On the other hand, the so-called trained immunity-based vaccines (TIbVs) can be designed to work as activators of innate immunity, leading to a more responsive immune environment with higher resistance to a secondary insult (related or non-related) (<xref rid="pathogens-12-01386-f003" ref-type="fig">Figure 3</xref>B). In essence, epigenetic reprogramming, metabolic alterations, and elevated cytokine production will lay the foundation for a broader-spectrum response, which will not only be beneficial against unrelated pathogens but also lead to an enhanced adaptive response upon subsequent immunizations with a specific antigen of interest. T and B cell proportions and functions (e.g., cell numbers, cytokine production, and proliferative rates) could be altered in this situation [<xref rid="B67-pathogens-12-01386" ref-type="bibr">67</xref>].</p><p>The TIBVs could prompt two scenarios. The first one (<xref rid="pathogens-12-01386-f003" ref-type="fig">Figure 3</xref>B, enhanced non-specific response) was intensively discussed due to the COVID-19 pandemic when the use of BCG or Measles&#8211;Mumps&#8211;Rubella (MMR) vaccines had been postulated to be protective against SARS-CoV-2 infection [<xref rid="B53-pathogens-12-01386" ref-type="bibr">53</xref>,<xref rid="B68-pathogens-12-01386" ref-type="bibr">68</xref>]. The hypothesis goes by using a TI-inducer (such as the BCG vaccine) as a suitable ready-to-implement countermeasure in an epidemic-like situation, especially for the most vulnerable individuals, until vaccines that are more appropriate are developed. Here, TI-inducers could comprise the use of whole microorganisms (like bacteria, fungi, or viruses), purified molecules (like flagellins, lipopolysaccharides, or glucans), or even fully inactivated bacterial formulations (such as the MV30) [<xref rid="B69-pathogens-12-01386" ref-type="bibr">69</xref>,<xref rid="B70-pathogens-12-01386" ref-type="bibr">70</xref>,<xref rid="B71-pathogens-12-01386" ref-type="bibr">71</xref>]. However, licensed vaccines with proven heterologous effects against other pathogens would stand as more practical in order to achieve population, as safety and regulatory measures would have already been addressed. Nevertheless, not limited to epidemic situations, the study of licensed vaccines associations with protection against heterologous infections could significantly add to the health service&#8217;s arsenal against diseases. For instance, Lee et al., 2018, suggest that the cold-adapted live attenuated influenza vaccine (CAIV) could provide NSEs against unrelated respiratory pathogens [<xref rid="B72-pathogens-12-01386" ref-type="bibr">72</xref>]. Despite a growing body of reports on the field, unfortunately, most of them lack deep evaluation of the TI mechanisms underlying the observed phenotypes.</p><p>The second scenario (<xref rid="pathogens-12-01386-f003" ref-type="fig">Figure 3</xref>B, trained immunity + enhanced specific responses) takes place in a more designed process. An immunization regimen could be conceptualized as a two-dose process (the priming dose consisting of a TI-inducer to potentialize the upcoming secondary immunization) or even mixing the inducer to a specific antigen. Leentjens et al., 2015, observed that immunization with the trivalent influenza vaccine (2013&#8211;2014 seasonal strains) 14 days after BCG immunization evoked significantly enhanced antibody responses marked by quicker seroconversion in immunized individuals [<xref rid="B73-pathogens-12-01386" ref-type="bibr">73</xref>]. Similar enhanced phenotypes were observed for vaccines designed against bacteria or their toxins (such as diphtheria, tetanus, and pneumococcal disease) when this BCG-training strategy was applied [<xref rid="B74-pathogens-12-01386" ref-type="bibr">74</xref>]. These findings highlight the importance of BCG immunization at birth, as it may work as a TI-based strategy for vaccines applied in infants [<xref rid="B74-pathogens-12-01386" ref-type="bibr">74</xref>,<xref rid="B75-pathogens-12-01386" ref-type="bibr">75</xref>]. As mentioned above, a methodological alternative for harnessing BCG adjuvant-like properties could be the administration of the antigen in association with the BCG in a one-dose immunization. Counoupas et al., 2021, demonstrated that a formulation containing BCG, the SARS-CoV-2 Spike protein, and Alum (there termed BCG:CoVac) was responsible for inducing elevated titers of neutralizing antibodies and Th1-biased cytokine response in K18-hACE2 mice [<xref rid="B76-pathogens-12-01386" ref-type="bibr">76</xref>]. This immunization regimen led to abrupt disease abrogation after the SARS-CoV-2 challenge, marked by a healthy clinical score of the mice, no body-weight loss, and no detectable viral titers in the lungs, with very few signs of tissue inflammation. Interestingly, when mice primed with BCG:CoVac was later boosted with a formulation containing only Spike and Alum, antibody responses were further augmented.</p><p>The previous approach has been investigated in another robust way: using a recombinant BCG (rBCG) strain able to express a specific antigen of interest. This methodology will combine the TI-inducer effects and the adjuvant-like properties of BCG with the adaptive-specific responses of a protein subunit vaccine in one single immunizer able to elicit strong cellular and humoral immune responses [<xref rid="B77-pathogens-12-01386" ref-type="bibr">77</xref>,<xref rid="B78-pathogens-12-01386" ref-type="bibr">78</xref>]. As the BCG replicates inside APCs, the initiation of the immune response can be improved, and its polarization may be directed by the BCG dose, as low doses are related to biased Th1 immune responses, while higher doses correlate with mixed Th1/Th2 immune responses [<xref rid="B78-pathogens-12-01386" ref-type="bibr">78</xref>]. Differently from the strategy of mixing BCG and antigen of interest, rBCG strains can be modified in order to evoke the best of the antigen immunogenicity. These adjustments can involve (1) mycobacterial signal sequences for driving antigen expression to the mycobacterium wall and enhancing recognition [<xref rid="B79-pathogens-12-01386" ref-type="bibr">79</xref>], (2) the use of stronger promoters for higher levels of antigen expression [<xref rid="B80-pathogens-12-01386" ref-type="bibr">80</xref>], or (3) the use of strains designed with the listeriolysin O from <italic toggle="yes">Listeria monocytogenes</italic>, a pore-forming protein which leads to leakage of the mycobacterium antigens, enhancing antigen processing and presentation by the host [<xref rid="B81-pathogens-12-01386" ref-type="bibr">81</xref>].</p><p>In a strategy for an experimental model of pertussis, Nascimento et al., 2000, evaluated a rBCG strain designed to express a genetically detoxified S1 subunit from a pertussis toxin (S1PT) in fusion with a &#946;-lactamase signal sequence (rBCG-S1PT) under the control of a strong promoter [<xref rid="B82-pathogens-12-01386" ref-type="bibr">82</xref>]. They reported that mice immunized with rBCG-S1PT presented a Th1-dominant immune response, being highly protected against intracerebral challenge with <italic toggle="yes">Bordetella pertussis</italic>. In a different strategy for an experimental model of leprosy, Ohara et al., 2001, assessed a rBCG strain overproducing three components against mycobacterium infection (rBCG/BA51) [<xref rid="B83-pathogens-12-01386" ref-type="bibr">83</xref>]. They observed that immunization of C57BL/6 and BALB/c mice led to reduced multiplication of the intracellular bacteria <italic toggle="yes">Mycobacterium leprae</italic> in their foot pads and elevated IFN-&#947; levels in their spleens (when cells were stimulated with <italic toggle="yes">M. leprae</italic> lysate). Not limited to bacterial infections, the rBCG system could be applied to other sorts of antigens, ranging from viral [<xref rid="B84-pathogens-12-01386" ref-type="bibr">84</xref>] to parasitic [<xref rid="B85-pathogens-12-01386" ref-type="bibr">85</xref>] molecules with elevated immune results.</p><p>Our group has recently demonstrated how combining all the immune features the rBCG system disposes of could potentiate protection against SARS-CoV-2 [<xref rid="B86-pathogens-12-01386" ref-type="bibr">86</xref>] in the K18-hACE2 murine model. We demonstrated mice immunized with rBCG-ChD6 (an rBCG strain expressing a chimeric protein based on immunodominant epitopes from Nucleocapsid and Spike proteins from SARS-CoV-2) followed by a booster dose containing the purified chimeric protein (rChimera), and Alum presented the best protective phenotypes. This immunization regimen induced the highest levels of antibodies against rChimera, neutralizing antibodies against SARS-CoV-2 and cytokine responses (IFN-&#947; and IL-6). These results were accompanied by IgG2c/IgG1 isotype switch, no body-weight loss in mice, and no detectable viable virus in their lungs. However, mice immunized with wild-type BCG followed by a booster dose with rChimera associated with Alum presented lower antibody levels, deteriorated clinical phenotype, and significantly higher viral load in their lungs (assessed by qPCR). When mice did not receive any BCG immunization, the detected cellular responses were correspondingly lower. Additionally, a double-dose rBCG-ChD6 immunization (no protein-Alum boost) was not protective. Taken together, these results showed that rBCG expressing target infection-related antigens is a more robust strategy for priming than wild-type BCG in this scenario. Further, rBCG immunization associated with standard specific antigen representation in a priming-boost strategy was crucial to significantly enhanced protection against SARS-CoV-2 infection. In conclusion, TIbVs represent a conceptually new field for vaccine design with a variety of possibilities to be explored. The upgrowing body of investigative research on TI mechanisms also highlights the importance of the clinical evaluation of existing vaccines regarding NSEs. Elucidating its mechanisms could aid translational studies, resulting in the rational design of more robust and protective vaccines for the population.</p></sec><sec id="sec7-pathogens-12-01386"><title>7. Concluding Remarks and Future Directions</title><p>The BCG is the most commonly administered vaccine in human history. Traditionally, this attenuated bacterium is used to prevent severe forms of tuberculosis in children. Furthermore, multiple studies have confirmed that this vaccine is indeed capable of triggering non-specific preventive or therapeutic beneficial effects against unrelated pathogens and cancer [<xref rid="B6-pathogens-12-01386" ref-type="bibr">6</xref>,<xref rid="B16-pathogens-12-01386" ref-type="bibr">16</xref>,<xref rid="B87-pathogens-12-01386" ref-type="bibr">87</xref>]. These non-specific BCG-mediated effects have been applied in clinical practice for about 40 years, consisting of the gold-standard intravesical therapy recommended to reduce the recurrence risk of non-muscle invasive bladder cancer after transurethral resection [<xref rid="B6-pathogens-12-01386" ref-type="bibr">6</xref>]. The mechanisms of bladder cancer treatment using BCG are currently under research. Recent findings suggest an important role for the adapter molecule MyD88 in association with a redundant function of Toll-like receptors (TLRs) 3, 7, and 9 [<xref rid="B87-pathogens-12-01386" ref-type="bibr">87</xref>].</p><p>Both innate and adaptive immune systems play a crucial role in producing heterologous effects. Trained immunity (TI), or innate immune memory, which is mainly demonstrated in myeloid and NK cells, has been shown to elicit an important role in BCG cross-protection against unrelated infections [<xref rid="B6-pathogens-12-01386" ref-type="bibr">6</xref>]. Moreover, TI can help manage nosocomial infections, such as skin infections and pneumonia. In mouse models, it was shown improved response to methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic>, <italic toggle="yes">Acinetobacter baumanii</italic>, multidrug-resistant <italic toggle="yes">Pseudomonas aeruginosa</italic>, and <italic toggle="yes">Klebsiella pneumoniae</italic> [<xref rid="B88-pathogens-12-01386" ref-type="bibr">88</xref>,<xref rid="B89-pathogens-12-01386" ref-type="bibr">89</xref>]. Therefore, exploring BCG can expand our understanding and application of TI in the clinical setting, which can ultimately lead to an improved quality of life for people.</p><p>The BCG-induced epigenetic and metabolic alterations were previously demonstrated in monocytes/macrophages, NK cells, and neutrophils. In addition, BCG also changed &#947;&#948; T cells&#8217; transcriptional programs and increased their responsiveness to heterologous bacterial and fungal stimuli, including LPS and <italic toggle="yes">Candida albicans</italic> [<xref rid="B90-pathogens-12-01386" ref-type="bibr">90</xref>]. More immune cell types are being involved in the process of TI, and its applications are increasing day by day. Finally, TI comprehension, including signaling pathways, cell-to-cell interactions, and durability, can be used to develop the next generation of vaccines to prevent or treat various infections and orphan diseases. This review discusses the mechanisms and protective role of TI against intracellular pathogens, focusing on integrating trained innate memory with adaptive memory to shape next-generation vaccines. Two important points for future direction are: (i) to determine new immune cell subpopulations involved in TI, spotlighting their activation process, and (ii) to identify new pathogens or their pathogen-associated molecular pattern as inducers of innate memory.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>A.C.V.S.C.d.A. and F.M. conceptualized this study; A.C.V.S.C.d.A., F.M., R.O.S., F.V.M. and S.C.O. wrote the original draft; A.C.V.S.C.d.A. wrote the final manuscript; A.C.V.S.C.d.A., F.V.M. and S.C.O. revised the manuscript and A.C.V.S.C.d.A., F.M. and R.O.S. made the figures. All authors listed have made a direct and intellectual contribution to the work. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-pathogens-12-01386"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lobo</surname><given-names>N.</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Zlotta</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Cirillo</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Boorjian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Black</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Meeks</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Bivalacqua</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Gontero</surname><given-names>P.</given-names></name><name name-style="western"><surname>Steinberg</surname><given-names>G.D.</given-names></name><etal/></person-group><article-title>100 years of Bacillus Calmette-Guerin immunotherapy: From cattle to COVID-19</article-title><source>Nat. Rev. Urol.</source><year>2021</year><volume>18</volume><fpage>611</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1038/s41585-021-00481-1</pub-id><pub-id pub-id-type="pmid">34131332</pub-id><pub-id pub-id-type="pmcid">PMC8204595</pub-id></element-citation></ref><ref id="B2-pathogens-12-01386"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Netea</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Bishai</surname><given-names>W.R.</given-names></name></person-group><article-title>BCG turns 100: Its nontraditional uses against viruses, cancer, and immunologic diseases</article-title><source>J. Clin. Investig.</source><year>2021</year><volume>131</volume><fpage>e148291</fpage><pub-id pub-id-type="doi">10.1172/JCI148291</pub-id><pub-id pub-id-type="pmid">34060492</pub-id><pub-id pub-id-type="pmcid">PMC8159679</pub-id></element-citation></ref><ref id="B3-pathogens-12-01386"><label>3.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>WHO</collab></person-group><source>Global Tuberculosis Report 2021</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2021</year><fpage>43</fpage></element-citation></ref><ref id="B4-pathogens-12-01386"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Butkeviciute</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S.G.</given-names></name></person-group><article-title>Heterologous effects of infant BCG vaccination: Potential mechanisms of immunity</article-title><source>Future Microbiol.</source><year>2018</year><volume>13</volume><fpage>1193</fpage><lpage>1208</lpage><pub-id pub-id-type="doi">10.2217/fmb-2018-0026</pub-id><pub-id pub-id-type="pmid">30117744</pub-id><pub-id pub-id-type="pmcid">PMC6190278</pub-id></element-citation></ref><ref id="B5-pathogens-12-01386"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Babjuk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Burger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Capoun</surname><given-names>O.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Comperat</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Dominguez Escrig</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Gontero</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liedberg</surname><given-names>F.</given-names></name><name name-style="western"><surname>Masson-Lecomte</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mostafid</surname><given-names>A.H.</given-names></name><etal/></person-group><article-title>European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma In Situ)</article-title><source>Eur. Urol.</source><year>2022</year><volume>81</volume><fpage>75</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2021.08.010</pub-id><pub-id pub-id-type="pmid">34511303</pub-id></element-citation></ref><ref id="B6-pathogens-12-01386"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Puffelen</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Novakovic</surname><given-names>B.</given-names></name><name name-style="western"><surname>van Emst</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kooper</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zuiverloon</surname><given-names>T.C.M.</given-names></name><name name-style="western"><surname>Oldenhof</surname><given-names>U.T.H.</given-names></name><name name-style="western"><surname>Witjes</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Galesloot</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Vrieling</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aben</surname><given-names>K.K.H.</given-names></name><etal/></person-group><article-title>Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections</article-title><source>J. Immunother. Cancer</source><year>2023</year><volume>11</volume><fpage>e005518</fpage><pub-id pub-id-type="doi">10.1136/jitc-2022-005518</pub-id><pub-id pub-id-type="pmid">36693678</pub-id><pub-id pub-id-type="pmcid">PMC9884868</pub-id></element-citation></ref><ref id="B7-pathogens-12-01386"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salem</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nofal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hosny</surname><given-names>D.</given-names></name></person-group><article-title>Treatment of common and plane warts in children with topical viable Bacillus Calmette-Guerin</article-title><source>Pediatr. Dermatol.</source><year>2013</year><volume>30</volume><fpage>60</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1111/j.1525-1470.2012.01848.x</pub-id><pub-id pub-id-type="pmid">22958215</pub-id></element-citation></ref><ref id="B8-pathogens-12-01386"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aaby</surname><given-names>P.</given-names></name><name name-style="western"><surname>Roth</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ravn</surname><given-names>H.</given-names></name><name name-style="western"><surname>Napirna</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lisse</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Stensballe</surname><given-names>L.</given-names></name><name name-style="western"><surname>Diness</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Lausch</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Lund</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Randomized trial of BCG vaccination at birth to low-birth-weight children: Beneficial nonspecific effects in the neonatal period?</article-title><source>J. Infect. Dis.</source><year>2011</year><volume>204</volume><fpage>245</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1093/infdis/jir240</pub-id><pub-id pub-id-type="pmid">21673035</pub-id></element-citation></ref><ref id="B9-pathogens-12-01386"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nemes</surname><given-names>E.</given-names></name><name name-style="western"><surname>Geldenhuys</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rozot</surname><given-names>V.</given-names></name><name name-style="western"><surname>Rutkowski</surname><given-names>K.T.</given-names></name><name name-style="western"><surname>Ratangee</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bilek</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mabwe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Makhethe</surname><given-names>L.</given-names></name><name name-style="western"><surname>Erasmus</surname><given-names>M.</given-names></name><name name-style="western"><surname>Toefy</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination</article-title><source>N. Engl. J. Med.</source><year>2018</year><volume>379</volume><fpage>138</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1714021</pub-id><pub-id pub-id-type="pmid">29996082</pub-id><pub-id pub-id-type="pmcid">PMC5937161</pub-id></element-citation></ref><ref id="B10-pathogens-12-01386"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giamarellos-Bourboulis</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Tsilika</surname><given-names>M.</given-names></name><name name-style="western"><surname>Moorlag</surname><given-names>S.</given-names></name><name name-style="western"><surname>Antonakos</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kotsaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dominguez-Andres</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kyriazopoulou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gkavogianni</surname><given-names>T.</given-names></name><name name-style="western"><surname>Adami</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Damoraki</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Activate: Randomized Clinical Trial of BCG Vaccination against Infection in the Elderly</article-title><source>Cell</source><year>2020</year><volume>183</volume><fpage>315</fpage><lpage>323.e9</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.08.051</pub-id><pub-id pub-id-type="pmid">32941801</pub-id><pub-id pub-id-type="pmcid">PMC7462457</pub-id></element-citation></ref><ref id="B11-pathogens-12-01386"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marchant</surname><given-names>A.</given-names></name><name name-style="western"><surname>Goetghebuer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ota</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Wolfe</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ceesay</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>De Groote</surname><given-names>D.</given-names></name><name name-style="western"><surname>Corrah</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wheeler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huygen</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guerin vaccination</article-title><source>J. Immunol.</source><year>1999</year><volume>163</volume><fpage>2249</fpage><lpage>2255</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.163.4.2249</pub-id><pub-id pub-id-type="pmid">10438968</pub-id></element-citation></ref><ref id="B12-pathogens-12-01386"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Messina</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Zimmermann</surname><given-names>P.</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>N.</given-names></name></person-group><article-title>The impact of vaccines on heterologous adaptive immunity</article-title><source>Clin. Microbiol. Infect.</source><year>2019</year><volume>25</volume><fpage>1484</fpage><lpage>1493</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2019.02.016</pub-id><pub-id pub-id-type="pmid">30797062</pub-id></element-citation></ref><ref id="B13-pathogens-12-01386"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quintin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Saeed</surname><given-names>S.</given-names></name><name name-style="western"><surname>Martens</surname><given-names>J.H.A.</given-names></name><name name-style="western"><surname>Giamarellos-Bourboulis</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Ifrim</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Logie</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kullberg</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Wijmenga</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes</article-title><source>Cell Host Microbe</source><year>2012</year><volume>12</volume><fpage>223</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2012.06.006</pub-id><pub-id pub-id-type="pmid">22901542</pub-id><pub-id pub-id-type="pmcid">PMC3864037</pub-id></element-citation></ref><ref id="B14-pathogens-12-01386"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kleinnijenhuis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Quintin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Preijers</surname><given-names>F.</given-names></name><name name-style="western"><surname>Joosten</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Ifrim</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Saeed</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>C.</given-names></name><name name-style="western"><surname>van Loenhout</surname><given-names>J.</given-names></name><name name-style="western"><surname>de Jong</surname><given-names>D.</given-names></name><name name-style="western"><surname>Stunnenberg</surname><given-names>H.G.</given-names></name><etal/></person-group><article-title>Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2012</year><volume>109</volume><fpage>17537</fpage><lpage>17542</lpage><pub-id pub-id-type="doi">10.1073/pnas.1202870109</pub-id><pub-id pub-id-type="pmid">22988082</pub-id><pub-id pub-id-type="pmcid">PMC3491454</pub-id></element-citation></ref><ref id="B15-pathogens-12-01386"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaufmann</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sanz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dunn</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mendonca</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Pacis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tzelepis</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pernet</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dumaine</surname><given-names>A.</given-names></name><name name-style="western"><surname>Grenier</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>BCG Educates Hematopoietic Stem Cells to Generate Protective Innate Immunity against Tuberculosis</article-title><source>Cell</source><year>2018</year><volume>172</volume><fpage>176</fpage><lpage>190.e19</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.12.031</pub-id><pub-id pub-id-type="pmid">29328912</pub-id></element-citation></ref><ref id="B16-pathogens-12-01386"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Araujo</surname><given-names>A.</given-names></name><name name-style="western"><surname>de Queiroz</surname><given-names>N.</given-names></name><name name-style="western"><surname>Marinho</surname><given-names>F.V.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>S.C.</given-names></name></person-group><article-title>Bacillus Calmette-Guerin-Trained Macrophages Elicit a Protective Inflammatory Response against the Pathogenic Bacteria Brucella abortus</article-title><source>J. Immunol.</source><year>2023</year><volume>211</volume><fpage>791</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.2200642</pub-id><pub-id pub-id-type="pmid">37477668</pub-id><pub-id pub-id-type="pmcid">PMC10530434</pub-id></element-citation></ref><ref id="B17-pathogens-12-01386"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Netea</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Quintin</surname><given-names>J.</given-names></name><name name-style="western"><surname>van der Meer</surname><given-names>J.W.</given-names></name></person-group><article-title>Trained immunity: A memory for innate host defense</article-title><source>Cell Host Microbe</source><year>2011</year><volume>9</volume><fpage>355</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2011.04.006</pub-id><pub-id pub-id-type="pmid">21575907</pub-id></element-citation></ref><ref id="B18-pathogens-12-01386"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saeed</surname><given-names>S.</given-names></name><name name-style="western"><surname>Quintin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kerstens</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Aghajanirefah</surname><given-names>A.</given-names></name><name name-style="western"><surname>Matarese</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Ratter</surname><given-names>J.</given-names></name><name name-style="western"><surname>Berentsen</surname><given-names>K.</given-names></name><name name-style="western"><surname>van der Ent</surname><given-names>M.A.</given-names></name><etal/></person-group><article-title>Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity</article-title><source>Science</source><year>2014</year><volume>345</volume><fpage>1251086</fpage><pub-id pub-id-type="doi">10.1126/science.1251086</pub-id><pub-id pub-id-type="pmid">25258085</pub-id><pub-id pub-id-type="pmcid">PMC4242194</pub-id></element-citation></ref><ref id="B19-pathogens-12-01386"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Quintin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cramer</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Shepardson</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Saeed</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Giamarellos-Bourboulis</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Martens</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Aghajanirefah</surname><given-names>A.</given-names></name><etal/></person-group><article-title>mTOR- and HIF-1alpha-mediated aerobic glycolysis as metabolic basis for trained immunity</article-title><source>Science</source><year>2014</year><volume>345</volume><fpage>1250684</fpage><pub-id pub-id-type="doi">10.1126/science.1250684</pub-id><pub-id pub-id-type="pmid">25258083</pub-id><pub-id pub-id-type="pmcid">PMC4226238</pub-id></element-citation></ref><ref id="B20-pathogens-12-01386"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arts</surname><given-names>R.J.W.</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>A.</given-names></name><name name-style="western"><surname>La Rocca</surname><given-names>C.</given-names></name><name name-style="western"><surname>Palma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>F.</given-names></name><name name-style="western"><surname>Silvestre</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kleinnijenhuis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lachmandas</surname><given-names>E.</given-names></name><name name-style="western"><surname>Goncalves</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Belinha</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Immunometabolic Pathways in BCG-Induced Trained Immunity</article-title><source>Cell Rep.</source><year>2016</year><volume>17</volume><fpage>2562</fpage><lpage>2571</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.11.011</pub-id><pub-id pub-id-type="pmid">27926861</pub-id><pub-id pub-id-type="pmcid">PMC5177620</pub-id></element-citation></ref><ref id="B21-pathogens-12-01386"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitroulis</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ruppova</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Grzybek</surname><given-names>M.</given-names></name><name name-style="western"><surname>Grinenko</surname><given-names>T.</given-names></name><name name-style="western"><surname>Eugster</surname><given-names>A.</given-names></name><name name-style="western"><surname>Troullinaki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Palladini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kourtzelis</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Modulation of Myelopoiesis Progenitors Is an Integral Component of Trained Immunity</article-title><source>Cell</source><year>2018</year><volume>172</volume><fpage>147</fpage><lpage>161.e12</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.11.034</pub-id><pub-id pub-id-type="pmid">29328910</pub-id><pub-id pub-id-type="pmcid">PMC5766828</pub-id></element-citation></ref><ref id="B22-pathogens-12-01386"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Netea</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Dominguez-Andres</surname><given-names>J.</given-names></name><name name-style="western"><surname>Barreiro</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Chavakis</surname><given-names>T.</given-names></name><name name-style="western"><surname>Divangahi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fuchs</surname><given-names>E.</given-names></name><name name-style="western"><surname>Joosten</surname><given-names>L.A.B.</given-names></name><name name-style="western"><surname>van der Meer</surname><given-names>J.W.M.</given-names></name><name name-style="western"><surname>Mhlanga</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Mulder</surname><given-names>W.J.M.</given-names></name><etal/></person-group><article-title>Defining trained immunity and its role in health and disease</article-title><source>Nat. Rev. Immunol.</source><year>2020</year><volume>20</volume><fpage>375</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-0285-6</pub-id><pub-id pub-id-type="pmid">32132681</pub-id><pub-id pub-id-type="pmcid">PMC7186935</pub-id></element-citation></ref><ref id="B23-pathogens-12-01386"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arts</surname><given-names>R.J.W.</given-names></name><name name-style="western"><surname>Moorlag</surname><given-names>S.</given-names></name><name name-style="western"><surname>Novakovic</surname><given-names>B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Oosting</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Xavier</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Wijmenga</surname><given-names>C.</given-names></name><name name-style="western"><surname>Joosten</surname><given-names>L.A.B.</given-names></name><etal/></person-group><article-title>BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity</article-title><source>Cell Host Microbe</source><year>2018</year><volume>23</volume><fpage>89</fpage><lpage>100.e5</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2017.12.010</pub-id><pub-id pub-id-type="pmid">29324233</pub-id></element-citation></ref><ref id="B24-pathogens-12-01386"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moorlag</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rodriguez-Rosales</surname><given-names>Y.A.</given-names></name><name name-style="western"><surname>Gillard</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fanucchi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Theunissen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Novakovic</surname><given-names>B.</given-names></name><name name-style="western"><surname>de Bont</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Negishi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fok</surname><given-names>E.T.</given-names></name><name name-style="western"><surname>Kalafati</surname><given-names>L.</given-names></name><etal/></person-group><article-title>BCG Vaccination Induces Long-Term Functional Reprogramming of Human Neutrophils</article-title><source>Cell Rep.</source><year>2020</year><volume>33</volume><fpage>108387</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2020.108387</pub-id><pub-id pub-id-type="pmid">33207187</pub-id><pub-id pub-id-type="pmcid">PMC7672522</pub-id></element-citation></ref><ref id="B25-pathogens-12-01386"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cirovic</surname><given-names>B.</given-names></name><name name-style="western"><surname>de Bree</surname><given-names>L.C.J.</given-names></name><name name-style="western"><surname>Groh</surname><given-names>L.</given-names></name><name name-style="western"><surname>Blok</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>J.</given-names></name><name name-style="western"><surname>van der Velden</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bremmers</surname><given-names>M.E.J.</given-names></name><name name-style="western"><surname>van Crevel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Handler</surname><given-names>K.</given-names></name><name name-style="western"><surname>Picelli</surname><given-names>S.</given-names></name><etal/></person-group><article-title>BCG Vaccination in Humans Elicits Trained Immunity via the Hematopoietic Progenitor Compartment</article-title><source>Cell Host Microbe</source><year>2020</year><volume>28</volume><fpage>322</fpage><lpage>334.e5</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2020.05.014</pub-id><pub-id pub-id-type="pmid">32544459</pub-id><pub-id pub-id-type="pmcid">PMC7295478</pub-id></element-citation></ref><ref id="B26-pathogens-12-01386"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Downey</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sanz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kaufmann</surname><given-names>E.</given-names></name><name name-style="western"><surname>Blankenhaus</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pacis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pernet</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cardoso</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nijnik</surname><given-names>A.</given-names></name><etal/></person-group><article-title><italic toggle="yes">M. tuberculosis</italic> Reprograms Hematopoietic Stem Cells to Limit Myelopoiesis and Impair Trained Immunity</article-title><source>Cell</source><year>2020</year><volume>183</volume><fpage>752</fpage><lpage>770.e22</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.09.062</pub-id><pub-id pub-id-type="pmid">33125891</pub-id><pub-id pub-id-type="pmcid">PMC7599081</pub-id></element-citation></ref><ref id="B27-pathogens-12-01386"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moorlag</surname><given-names>S.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Novakovic</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kaufmann</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>T.</given-names></name><name name-style="western"><surname>van Crevel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Divangahi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Netea</surname><given-names>M.G.</given-names></name></person-group><article-title>beta-Glucan Induces Protective Trained Immunity against Mycobacterium tuberculosis Infection: A Key Role for IL-1</article-title><source>Cell Rep.</source><year>2020</year><volume>31</volume><fpage>107634</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2020.107634</pub-id><pub-id pub-id-type="pmid">32433977</pub-id><pub-id pub-id-type="pmcid">PMC7242907</pub-id></element-citation></ref><ref id="B28-pathogens-12-01386"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wellen</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Hatzivassiliou</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sachdeva</surname><given-names>U.M.</given-names></name><name name-style="western"><surname>Bui</surname><given-names>T.V.</given-names></name><name name-style="western"><surname>Cross</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>C.B.</given-names></name></person-group><article-title>ATP-citrate lyase links cellular metabolism to histone acetylation</article-title><source>Science</source><year>2009</year><volume>324</volume><fpage>1076</fpage><lpage>1080</lpage><pub-id pub-id-type="doi">10.1126/science.1164097</pub-id><pub-id pub-id-type="pmid">19461003</pub-id><pub-id pub-id-type="pmcid">PMC2746744</pub-id></element-citation></ref><ref id="B29-pathogens-12-01386"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaufmann</surname><given-names>E.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Ulndreaj</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pernet</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fontes</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lupien</surname><given-names>A.</given-names></name><name name-style="western"><surname>Desmeules</surname><given-names>P.</given-names></name><name name-style="western"><surname>McIntosh</surname><given-names>F.</given-names></name><name name-style="western"><surname>Abow</surname><given-names>A.</given-names></name><etal/></person-group><article-title>BCG vaccination provides protection against IAV but not SARS-CoV-2</article-title><source>Cell Rep.</source><year>2022</year><volume>38</volume><fpage>110502</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2022.110502</pub-id><pub-id pub-id-type="pmid">35235831</pub-id><pub-id pub-id-type="pmcid">PMC8858710</pub-id></element-citation></ref><ref id="B30-pathogens-12-01386"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dos Santos</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Barroso de Figueiredo</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Teodoro Silva</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Cirovic</surname><given-names>B.</given-names></name><name name-style="western"><surname>de Bree</surname><given-names>L.C.J.</given-names></name><name name-style="western"><surname>Damen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Moorlag</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Helsen</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Oosting</surname><given-names>M.</given-names></name><etal/></person-group><article-title>beta-Glucan-Induced Trained Immunity Protects against Leishmania braziliensis Infection: A Crucial Role for IL-32</article-title><source>Cell Rep.</source><year>2019</year><volume>28</volume><fpage>2659</fpage><lpage>2672.e6</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.08.004</pub-id><pub-id pub-id-type="pmid">31484076</pub-id></element-citation></ref><ref id="B31-pathogens-12-01386"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lachmandas</surname><given-names>E.</given-names></name><name name-style="western"><surname>Beigier-Bompadre</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>V.</given-names></name><name name-style="western"><surname>van Laarhoven</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ammerdorffer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Boutens</surname><given-names>L.</given-names></name><name name-style="western"><surname>de Jong</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kanneganti</surname><given-names>T.D.</given-names></name><etal/></person-group><article-title>Rewiring cellular metabolism via the AKT/mTOR pathway contributes to host defence against Mycobacterium tuberculosis in human and murine cells</article-title><source>Eur. J. Immunol.</source><year>2016</year><volume>46</volume><fpage>2574</fpage><lpage>2586</lpage><pub-id pub-id-type="doi">10.1002/eji.201546259</pub-id><pub-id pub-id-type="pmid">27624090</pub-id><pub-id pub-id-type="pmcid">PMC5129526</pub-id></element-citation></ref><ref id="B32-pathogens-12-01386"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Z.X.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X.Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.L.</given-names></name><etal/></person-group><article-title>Akt, mTOR and NF-kappaB pathway activation in Treponema pallidum stimulates M1 macrophages</article-title><source>Int. Immunopharmacol.</source><year>2018</year><volume>59</volume><fpage>181</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2018.03.040</pub-id><pub-id pub-id-type="pmid">29656208</pub-id></element-citation></ref><ref id="B33-pathogens-12-01386"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>X.H.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.Y.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lou</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>D.L.</given-names></name></person-group><article-title>NLRP3 and mTOR Reciprocally Regulate Macrophage Phagolysosome Formation and Acidification Against Vibrio vulnificus Infection</article-title><source>Front. Cell Dev. Biol.</source><year>2020</year><volume>8</volume><elocation-id>587961</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2020.587961</pub-id><pub-id pub-id-type="pmid">33117816</pub-id><pub-id pub-id-type="pmcid">PMC7578225</pub-id></element-citation></ref><ref id="B34-pathogens-12-01386"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hammer</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Romagnani</surname><given-names>C.</given-names></name></person-group><article-title>About Training and Memory: NK-Cell Adaptation to Viral Infections</article-title><source>Adv. Immunol.</source><year>2017</year><volume>133</volume><fpage>171</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1016/bs.ai.2016.10.001</pub-id><pub-id pub-id-type="pmid">28215279</pub-id></element-citation></ref><ref id="B35-pathogens-12-01386"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stary</surname><given-names>V.</given-names></name><name name-style="western"><surname>Stary</surname><given-names>G.</given-names></name></person-group><article-title>NK Cell-Mediated Recall Responses: Memory-Like, Adaptive, or Antigen-Specific?</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2020</year><volume>10</volume><elocation-id>208</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2020.00208</pub-id><pub-id pub-id-type="pmid">32477964</pub-id><pub-id pub-id-type="pmcid">PMC7240046</pub-id></element-citation></ref><ref id="B36-pathogens-12-01386"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Terren</surname><given-names>I.</given-names></name><name name-style="western"><surname>Orrantia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Astarloa-Pando</surname><given-names>G.</given-names></name><name name-style="western"><surname>Amarilla-Irusta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zenarruzabeitia</surname><given-names>O.</given-names></name><name name-style="western"><surname>Borrego</surname><given-names>F.</given-names></name></person-group><article-title>Cytokine-Induced Memory-Like NK Cells: From the Basics to Clinical Applications</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><fpage>884648</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.884648</pub-id><pub-id pub-id-type="pmid">35603208</pub-id><pub-id pub-id-type="pmcid">PMC9114299</pub-id></element-citation></ref><ref id="B37-pathogens-12-01386"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hole</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Wager</surname><given-names>C.M.L.</given-names></name><name name-style="western"><surname>Castro-Lopez</surname><given-names>N.</given-names></name><name name-style="western"><surname>Campuzano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wozniak</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wormley</surname><given-names>F.L.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Induction of memory-like dendritic cell responses in vivo</article-title><source>Nat. Commun.</source><year>2019</year><volume>10</volume><fpage>2955</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-10486-5</pub-id><pub-id pub-id-type="pmid">31273203</pub-id><pub-id pub-id-type="pmcid">PMC6609631</pub-id></element-citation></ref><ref id="B38-pathogens-12-01386"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eastman</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bermik</surname><given-names>J.</given-names></name><name name-style="western"><surname>Potchen</surname><given-names>N.</given-names></name><name name-style="western"><surname>den Dekker</surname><given-names>A.</given-names></name><name name-style="western"><surname>Neal</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Malachowski</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schaller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kunkel</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Epigenetic stabilization of DC and DC precursor classical activation by TNFalpha contributes to protective T cell polarization</article-title><source>Sci. Adv.</source><year>2019</year><volume>5</volume><fpage>eaaw9051</fpage><pub-id pub-id-type="doi">10.1126/sciadv.aaw9051</pub-id><pub-id pub-id-type="pmid">31840058</pub-id><pub-id pub-id-type="pmcid">PMC6892624</pub-id></element-citation></ref><ref id="B39-pathogens-12-01386"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jeyanathan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Haddadi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Barra</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Vaseghi-Shanjani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Damjanovic</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>R.</given-names></name><name name-style="western"><surname>Afkhami</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dvorkin-Gheva</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Induction of Autonomous Memory Alveolar Macrophages Requires T Cell Help and Is Critical to Trained Immunity</article-title><source>Cell</source><year>2018</year><volume>175</volume><fpage>1634</fpage><lpage>1650.e17</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.09.042</pub-id><pub-id pub-id-type="pmid">30433869</pub-id></element-citation></ref><ref id="B40-pathogens-12-01386"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Minns</surname><given-names>D.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Findlay</surname><given-names>E.G.</given-names></name></person-group><article-title>Orchestration of Adaptive T Cell Responses by Neutrophil Granule Contents</article-title><source>Mediat. Inflamm.</source><year>2019</year><volume>2019</volume><fpage>8968943</fpage><pub-id pub-id-type="doi">10.1155/2019/8968943</pub-id><pub-id pub-id-type="pmcid">PMC6431490</pub-id><pub-id pub-id-type="pmid">30983883</pub-id></element-citation></ref><ref id="B41-pathogens-12-01386"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosales</surname><given-names>C.</given-names></name></person-group><article-title>Neutrophil: A Cell with Many Roles in Inflammation or Several Cell Types?</article-title><source>Front. Physiol.</source><year>2018</year><volume>9</volume><fpage>113</fpage><pub-id pub-id-type="doi">10.3389/fphys.2018.00113</pub-id><pub-id pub-id-type="pmid">29515456</pub-id><pub-id pub-id-type="pmcid">PMC5826082</pub-id></element-citation></ref><ref id="B42-pathogens-12-01386"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Millman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Craft</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Boucher</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Urban</surname><given-names>J.F.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Kim</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Gause</surname><given-names>W.C.</given-names></name></person-group><article-title>Neutrophils prime a long-lived effector macrophage phenotype that mediates accelerated helminth expulsion</article-title><source>Nat. Immunol.</source><year>2014</year><volume>15</volume><fpage>938</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1038/ni.2984</pub-id><pub-id pub-id-type="pmid">25173346</pub-id><pub-id pub-id-type="pmcid">PMC4479254</pub-id></element-citation></ref><ref id="B43-pathogens-12-01386"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jensen</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Larsen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Biering-Sorensen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Eriksen</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Monteiro</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hougaard</surname><given-names>D.</given-names></name><name name-style="western"><surname>Aaby</surname><given-names>P.</given-names></name><name name-style="western"><surname>Netea</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Flanagan</surname><given-names>K.L.</given-names></name><etal/></person-group><article-title>Heterologous immunological effects of early BCG vaccination in low-birth-weight infants in Guinea-Bissau: A randomized-controlled trial</article-title><source>J. Infect. Dis.</source><year>2015</year><volume>211</volume><fpage>956</fpage><lpage>967</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiu508</pub-id><pub-id pub-id-type="pmid">25210141</pub-id><pub-id pub-id-type="pmcid">PMC4340366</pub-id></element-citation></ref><ref id="B44-pathogens-12-01386"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moorlag</surname><given-names>S.</given-names></name><name name-style="western"><surname>Arts</surname><given-names>R.J.W.</given-names></name><name name-style="western"><surname>van Crevel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Netea</surname><given-names>M.G.</given-names></name></person-group><article-title>Non-specific effects of BCG vaccine on viral infections</article-title><source>Clin. Microbiol. Infect.</source><year>2019</year><volume>25</volume><fpage>1473</fpage><lpage>1478</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2019.04.020</pub-id><pub-id pub-id-type="pmid">31055165</pub-id></element-citation></ref><ref id="B45-pathogens-12-01386"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kleinnijenhuis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Quintin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Preijers</surname><given-names>F.</given-names></name><name name-style="western"><surname>Benn</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Joosten</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>C.</given-names></name><name name-style="western"><surname>van Loenhout</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xavier</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Aaby</surname><given-names>P.</given-names></name><name name-style="western"><surname>van der Meer</surname><given-names>J.W.</given-names></name><etal/></person-group><article-title>Long-lasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity</article-title><source>J. Innate Immun.</source><year>2014</year><volume>6</volume><fpage>152</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1159/000355628</pub-id><pub-id pub-id-type="pmid">24192057</pub-id><pub-id pub-id-type="pmcid">PMC3944069</pub-id></element-citation></ref><ref id="B46-pathogens-12-01386"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spencer</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Ganguly</surname><given-names>R.</given-names></name><name name-style="western"><surname>Waldman</surname><given-names>R.H.</given-names></name></person-group><article-title>Nonspecific protection of mice against influenza virus infection by local or systemic immunization with Bacille Calmette-Guerin</article-title><source>J. Infect. Dis.</source><year>1977</year><volume>136</volume><fpage>171</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1093/infdis/136.2.171</pub-id><pub-id pub-id-type="pmid">894076</pub-id></element-citation></ref><ref id="B47-pathogens-12-01386"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suenaga</surname><given-names>T.</given-names></name><name name-style="western"><surname>Okuyama</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>I.</given-names></name><name name-style="western"><surname>Azuma</surname><given-names>M.</given-names></name></person-group><article-title>Effect of Mycobacterium tuberculosis BCG infection on the resistance of mice to ectromelia virus infection: Participation of interferon in enhanced resistance</article-title><source>Infect. Immun.</source><year>1978</year><volume>20</volume><fpage>312</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1128/iai.20.1.312-314.1978</pub-id><pub-id pub-id-type="pmid">208973</pub-id><pub-id pub-id-type="pmcid">PMC421853</pub-id></element-citation></ref><ref id="B48-pathogens-12-01386"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakuma</surname><given-names>T.</given-names></name><name name-style="western"><surname>Suenaga</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>I.</given-names></name><name name-style="western"><surname>Azuma</surname><given-names>M.</given-names></name></person-group><article-title>Mechanisms of enhanced resistance of <italic toggle="yes">Mycobacterium bovis</italic> BCG-treated mice to ectromelia virus infection</article-title><source>Infect. Immun.</source><year>1983</year><volume>42</volume><fpage>567</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1128/iai.42.2.567-573.1983</pub-id><pub-id pub-id-type="pmid">6315580</pub-id><pub-id pub-id-type="pmcid">PMC264465</pub-id></element-citation></ref><ref id="B49-pathogens-12-01386"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lodmell</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Ewalt</surname><given-names>L.C.</given-names></name></person-group><article-title>Enhanced resistance against encephalomyocarditis virus infection in mice, induced by a nonviable <italic toggle="yes">Mycobacterium tuberculosis</italic> oil-droplet vaccine</article-title><source>Infect. Immun.</source><year>1978</year><volume>19</volume><fpage>225</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1128/iai.19.1.225-230.1978</pub-id><pub-id pub-id-type="pmid">203533</pub-id><pub-id pub-id-type="pmcid">PMC414071</pub-id></element-citation></ref><ref id="B50-pathogens-12-01386"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lodmell</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Ewalt</surname><given-names>L.C.</given-names></name></person-group><article-title>Induction of enhanced resistance against encephalomyocarditis virus infection of mice by nonviable <italic toggle="yes">Mycobacterium tuberculosis</italic>: Mechanisms of protection</article-title><source>Infect. Immun.</source><year>1978</year><volume>22</volume><fpage>740</fpage><lpage>745</lpage><pub-id pub-id-type="doi">10.1128/iai.22.3.740-745.1978</pub-id><pub-id pub-id-type="pmid">215550</pub-id><pub-id pub-id-type="pmcid">PMC422222</pub-id></element-citation></ref><ref id="B51-pathogens-12-01386"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathurin</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Martens</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Kornfeld</surname><given-names>H.</given-names></name><name name-style="western"><surname>Welsh</surname><given-names>R.M.</given-names></name></person-group><article-title>CD4 T-cell-mediated heterologous immunity between mycobacteria and poxviruses</article-title><source>J. Virol.</source><year>2009</year><volume>83</volume><fpage>3528</fpage><lpage>3539</lpage><pub-id pub-id-type="doi">10.1128/JVI.02393-08</pub-id><pub-id pub-id-type="pmid">19193795</pub-id><pub-id pub-id-type="pmcid">PMC2663272</pub-id></element-citation></ref><ref id="B52-pathogens-12-01386"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charoenlap</surname><given-names>S.</given-names></name><name name-style="western"><surname>Piromsopa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Charoenlap</surname><given-names>C.</given-names></name></person-group><article-title>Potential role of Bacillus Calmette-Guerin (BCG) vaccination in COVID-19 pandemic mortality: Epidemiological and Immunological aspects</article-title><source>Asian Pac. J. Allergy Immunol.</source><year>2020</year><volume>38</volume><fpage>150</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.12932/AP-310520-0863</pub-id><pub-id pub-id-type="pmid">32686943</pub-id></element-citation></ref><ref id="B53-pathogens-12-01386"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koneru</surname><given-names>G.</given-names></name><name name-style="western"><surname>Batiha</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Algammal</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Mabrok</surname><given-names>M.</given-names></name><name name-style="western"><surname>Magdy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sayed</surname><given-names>S.</given-names></name><name name-style="western"><surname>AbuElmagd</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Elnemr</surname><given-names>R.</given-names></name><name name-style="western"><surname>Saad</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Abd Ellah</surname><given-names>N.H.</given-names></name><etal/></person-group><article-title>BCG Vaccine-Induced Trained Immunity and COVID-19: Protective or Bystander?</article-title><source>Infect. Drug Resist.</source><year>2021</year><volume>14</volume><fpage>1169</fpage><lpage>1184</lpage><pub-id pub-id-type="doi">10.2147/IDR.S300162</pub-id><pub-id pub-id-type="pmid">33790587</pub-id><pub-id pub-id-type="pmcid">PMC8001200</pub-id></element-citation></ref><ref id="B54-pathogens-12-01386"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hilligan</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Namasivayam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sher</surname><given-names>A.</given-names></name></person-group><article-title>BCG mediated protection of the lung against experimental SARS-CoV-2 infection</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><fpage>1232764</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1232764</pub-id><pub-id pub-id-type="pmid">37744331</pub-id><pub-id pub-id-type="pmcid">PMC10514903</pub-id></element-citation></ref><ref id="B55-pathogens-12-01386"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>B.Z.</given-names></name><name name-style="western"><surname>Shuai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yuen</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.L.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Bacillus Calmette-Guerin-induced trained immunity protects against SARS-CoV-2 challenge in K18-hACE2 mice</article-title><source>JCI Insight</source><year>2022</year><volume>7</volume><fpage>e157393</fpage><pub-id pub-id-type="doi">10.1172/jci.insight.157393</pub-id><pub-id pub-id-type="pmid">35446790</pub-id><pub-id pub-id-type="pmcid">PMC9220951</pub-id></element-citation></ref><ref id="B56-pathogens-12-01386"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lombardo</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Praharaj</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bullen</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Um</surname><given-names>P.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Komm</surname><given-names>O.</given-names></name><name name-style="western"><surname>Illei</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Ordonez</surname><given-names>A.A.</given-names></name><etal/></person-group><article-title>Dynamic single-cell RNA sequencing reveals BCG vaccination curtails SARS-CoV-2 induced disease severity and lung inflammation</article-title><source>bioRxiv</source><year>2022</year><pub-id pub-id-type="doi">10.1101/2022.03.15.484018</pub-id></element-citation></ref><ref id="B57-pathogens-12-01386"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hilligan</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Namasivayam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Clancy</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>O&#8217;Mard</surname><given-names>D.</given-names></name><name name-style="western"><surname>Oland</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Castro</surname><given-names>E.</given-names></name><name name-style="western"><surname>Garza</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Lafont</surname><given-names>B.A.P.</given-names></name><etal/></person-group><article-title>Intravenous administration of BCG protects mice against lethal SARS-CoV-2 challenge</article-title><source>J. Exp. Med.</source><year>2022</year><volume>219</volume><fpage>e20211862</fpage><pub-id pub-id-type="doi">10.1084/jem.20211862</pub-id><pub-id pub-id-type="pmid">34889942</pub-id><pub-id pub-id-type="pmcid">PMC8669500</pub-id></element-citation></ref><ref id="B58-pathogens-12-01386"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Sibley</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sarfas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Morrison</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Bewley</surname><given-names>K.</given-names></name><name name-style="western"><surname>Churchward</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fotheringham</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gkolfinos</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gooch</surname><given-names>K.</given-names></name><name name-style="western"><surname>Handley</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Influence of Aerosol Delivered BCG Vaccination on Immunological and Disease Parameters Following SARS-CoV-2 Challenge in Rhesus Macaques</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><fpage>801799</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2021.801799</pub-id><pub-id pub-id-type="pmid">35222355</pub-id><pub-id pub-id-type="pmcid">PMC8863871</pub-id></element-citation></ref><ref id="B59-pathogens-12-01386"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Netea</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Ziogas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Benn</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Giamarellos-Bourboulis</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Joosten</surname><given-names>L.A.B.</given-names></name><name name-style="western"><surname>Arditi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chumakov</surname><given-names>K.</given-names></name><name name-style="western"><surname>van Crevel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gallo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Aaby</surname><given-names>P.</given-names></name><etal/></person-group><article-title>The role of trained immunity in COVID-19: Lessons for the next pandemic</article-title><source>Cell Host Microbe</source><year>2023</year><volume>31</volume><fpage>890</fpage><lpage>901</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2023.05.004</pub-id><pub-id pub-id-type="pmid">37321172</pub-id><pub-id pub-id-type="pmcid">PMC10265767</pub-id></element-citation></ref><ref id="B60-pathogens-12-01386"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kleinnijenhuis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Quintin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Preijers</surname><given-names>F.</given-names></name><name name-style="western"><surname>Joosten</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xavier</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>van der Meer</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>van Crevel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Netea</surname><given-names>M.G.</given-names></name></person-group><article-title>BCG-induced trained immunity in NK cells: Role for non-specific protection to infection</article-title><source>Clin. Immunol.</source><year>2014</year><volume>155</volume><fpage>213</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1016/j.clim.2014.10.005</pub-id><pub-id pub-id-type="pmid">25451159</pub-id><pub-id pub-id-type="pmcid">PMC5084088</pub-id></element-citation></ref><ref id="B61-pathogens-12-01386"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silva</surname><given-names>M.V.T.</given-names></name><name name-style="western"><surname>Dos Santos</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Figueiredo</surname><given-names>A.M.B.</given-names></name><name name-style="western"><surname>Teufel</surname><given-names>L.U.</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>J.X.</given-names></name><name name-style="western"><surname>Matos</surname><given-names>G.G.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Netea</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Joosten</surname><given-names>L.A.B.</given-names></name><etal/></person-group><article-title>The role of IL-32 in Bacillus Calmette-Guerin (BCG)-induced trained immunity in infections caused by different <italic toggle="yes">Leishmania</italic> spp.</article-title><source>Microb. Pathog.</source><year>2021</year><volume>158</volume><fpage>105088</fpage><pub-id pub-id-type="doi">10.1016/j.micpath.2021.105088</pub-id><pub-id pub-id-type="pmid">34260904</pub-id></element-citation></ref><ref id="B62-pathogens-12-01386"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parra</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Derrick</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kolibab</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>S.L.</given-names></name></person-group><article-title>Molecular analysis of non-specific protection against murine malaria induced by BCG vaccination</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e66115</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0066115</pub-id><pub-id pub-id-type="pmid">23861742</pub-id><pub-id pub-id-type="pmcid">PMC3701530</pub-id></element-citation></ref><ref id="B63-pathogens-12-01386"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>G.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Afkhami</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bavananthasivam</surname><given-names>J.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Vaseghi-Shanjani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aleithan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zganiacz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jeyanathan</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Subcutaneous BCG vaccination protects against streptococcal pneumonia via regulating innate immune responses in the lung</article-title><source>EMBO Mol. Med.</source><year>2023</year><volume>15</volume><fpage>e17084</fpage><pub-id pub-id-type="doi">10.15252/emmm.202217084</pub-id><pub-id pub-id-type="pmid">37158369</pub-id><pub-id pub-id-type="pmcid">PMC10331578</pub-id></element-citation></ref><ref id="B64-pathogens-12-01386"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mata</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tarancon</surname><given-names>R.</given-names></name><name name-style="western"><surname>Guerrero</surname><given-names>C.</given-names></name><name name-style="western"><surname>Moreo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Moreau</surname><given-names>F.</given-names></name><name name-style="western"><surname>Uranga</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gomez</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Marinova</surname><given-names>D.</given-names></name><name name-style="western"><surname>Domenech</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gonzalez-Camacho</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Pulmonary BCG induces lung-resident macrophage activation and confers long-term protection against tuberculosis</article-title><source>Sci. Immunol.</source><year>2021</year><volume>6</volume><fpage>eabc2934</fpage><pub-id pub-id-type="doi">10.1126/sciimmunol.abc2934</pub-id><pub-id pub-id-type="pmid">34559551</pub-id></element-citation></ref><ref id="B65-pathogens-12-01386"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gebre</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Brito</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Tostanoski</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Carfi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barouch</surname><given-names>D.H.</given-names></name></person-group><article-title>Novel approaches for vaccine development</article-title><source>Cell</source><year>2021</year><volume>184</volume><fpage>1589</fpage><lpage>1603</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.02.030</pub-id><pub-id pub-id-type="pmid">33740454</pub-id><pub-id pub-id-type="pmcid">PMC8049514</pub-id></element-citation></ref><ref id="B66-pathogens-12-01386"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pulendran</surname><given-names>B.</given-names></name><name name-style="western"><surname>Arunachalam</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>D.T.</given-names></name></person-group><article-title>Emerging concepts in the science of vaccine adjuvants</article-title><source>Nat. Rev. Drug Discov.</source><year>2021</year><volume>20</volume><fpage>454</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1038/s41573-021-00163-y</pub-id><pub-id pub-id-type="pmid">33824489</pub-id><pub-id pub-id-type="pmcid">PMC8023785</pub-id></element-citation></ref><ref id="B67-pathogens-12-01386"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wimmers</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pulendran</surname><given-names>B.</given-names></name></person-group><article-title>Epigenetic adjuvants: Durable reprogramming of the innate immune system with adjuvants</article-title><source>Curr. Opin. Immunol.</source><year>2022</year><volume>77</volume><fpage>102189</fpage><pub-id pub-id-type="doi">10.1016/j.coi.2022.102189</pub-id><pub-id pub-id-type="pmid">35588691</pub-id><pub-id pub-id-type="pmcid">PMC9924100</pub-id></element-citation></ref><ref id="B68-pathogens-12-01386"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bayram</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Musharrafieh</surname><given-names>U.</given-names></name><name name-style="western"><surname>Bizri</surname><given-names>A.R.</given-names></name></person-group><article-title>Revisiting the potential role of BCG and MMR vaccines in COVID-19</article-title><source>Sci. Prog.</source><year>2022</year><volume>105</volume><fpage>368504221105172</fpage><pub-id pub-id-type="doi">10.1177/00368504221105172</pub-id><pub-id pub-id-type="pmid">35848578</pub-id><pub-id pub-id-type="pmcid">PMC10450304</pub-id></element-citation></ref><ref id="B69-pathogens-12-01386"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barton</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>White</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Cathelyn</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Brett-McClellan</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Engle</surname><given-names>M.</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>V.L.</given-names></name><name name-style="western"><surname>Virgin</surname><given-names>H.W.T.</given-names></name></person-group><article-title>Herpesvirus latency confers symbiotic protection from bacterial infection</article-title><source>Nature</source><year>2007</year><volume>447</volume><fpage>326</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1038/nature05762</pub-id><pub-id pub-id-type="pmid">17507983</pub-id></element-citation></ref><ref id="B70-pathogens-12-01386"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ifrim</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Quintin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Joosten</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gow</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>van der Meer</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Netea</surname><given-names>M.G.</given-names></name></person-group><article-title>Trained immunity or tolerance: Opposing functional programs induced in human monocytes after engagement of various pattern recognition receptors</article-title><source>Clin. Vaccine Immunol.</source><year>2014</year><volume>21</volume><fpage>534</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1128/CVI.00688-13</pub-id><pub-id pub-id-type="pmid">24521784</pub-id><pub-id pub-id-type="pmcid">PMC3993125</pub-id></element-citation></ref><ref id="B71-pathogens-12-01386"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guevara-Hoyer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Saz-Leal</surname><given-names>P.</given-names></name><name name-style="western"><surname>Diez-Rivero</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Ochoa-Grullon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fernandez-Arquero</surname><given-names>M.</given-names></name><name name-style="western"><surname>Perez de Diego</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sanchez-Ramon</surname><given-names>S.</given-names></name></person-group><article-title>Trained Immunity Based-Vaccines as a Prophylactic Strategy in Common Variable Immunodeficiency. A Proof of Concept Study</article-title><source>Biomedicines</source><year>2020</year><volume>8</volume><elocation-id>203</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines8070203</pub-id><pub-id pub-id-type="pmid">32660100</pub-id><pub-id pub-id-type="pmcid">PMC7400202</pub-id></element-citation></ref><ref id="B72-pathogens-12-01386"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>S.U.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Seong</surname><given-names>B.L.</given-names></name></person-group><article-title>Non-specific Effect of Vaccines: Immediate Protection against Respiratory Syncytial Virus Infection by a Live Attenuated Influenza Vaccine</article-title><source>Front. Microbiol.</source><year>2018</year><volume>9</volume><elocation-id>83</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2018.00083</pub-id><pub-id pub-id-type="pmid">29445364</pub-id><pub-id pub-id-type="pmcid">PMC5797773</pub-id></element-citation></ref><ref id="B73-pathogens-12-01386"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leentjens</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kox</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stokman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gerretsen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Diavatopoulos</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>van Crevel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rimmelzwaan</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Pickkers</surname><given-names>P.</given-names></name><name name-style="western"><surname>Netea</surname><given-names>M.G.</given-names></name></person-group><article-title>BCG Vaccination Enhances the Immunogenicity of Subsequent Influenza Vaccination in Healthy Volunteers: A Randomized, Placebo-Controlled Pilot Study</article-title><source>J. Infect. Dis.</source><year>2015</year><volume>212</volume><fpage>1930</fpage><lpage>1938</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiv332</pub-id><pub-id pub-id-type="pmid">26071565</pub-id></element-citation></ref><ref id="B74-pathogens-12-01386"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zimmermann</surname><given-names>P.</given-names></name><name name-style="western"><surname>Donath</surname><given-names>S.</given-names></name><name name-style="western"><surname>Perrett</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Messina</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Ritz</surname><given-names>N.</given-names></name><name name-style="western"><surname>Netea</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Flanagan</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>van der Klis</surname><given-names>F.R.M.</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>N.</given-names></name><collab>MIS BAIR Group</collab></person-group><article-title>The influence of neonatal Bacille Calmette-Guerin (BCG) immunisation on heterologous vaccine responses in infants</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><fpage>3735</fpage><lpage>3744</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.03.016</pub-id><pub-id pub-id-type="pmid">31153688</pub-id></element-citation></ref><ref id="B75-pathogens-12-01386"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Libraty</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Woda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Acosta</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Obcena</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brion</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Capeding</surname><given-names>R.Z.</given-names></name></person-group><article-title>Neonatal BCG vaccination is associated with enhanced T-helper 1 immune responses to heterologous infant vaccines</article-title><source>Trials Vaccinol.</source><year>2014</year><volume>3</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.trivac.2013.11.004</pub-id><pub-id pub-id-type="pmid">24611083</pub-id><pub-id pub-id-type="pmcid">PMC3943168</pub-id></element-citation></ref><ref id="B76-pathogens-12-01386"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Counoupas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Johansen</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Stella</surname><given-names>A.O.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Aggarwal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bhattacharyya</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Grey</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hutchings</surname><given-names>O.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>K.</given-names></name><etal/></person-group><article-title>A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilising immunity against SARS-CoV-2 infection</article-title><source>NPJ Vaccines</source><year>2021</year><volume>6</volume><fpage>143</fpage><pub-id pub-id-type="doi">10.1038/s41541-021-00406-4</pub-id><pub-id pub-id-type="pmid">34848711</pub-id><pub-id pub-id-type="pmcid">PMC8633321</pub-id></element-citation></ref><ref id="B77-pathogens-12-01386"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mouhoub</surname><given-names>E.</given-names></name><name name-style="western"><surname>Domenech</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ndao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>M.B.</given-names></name></person-group><article-title>The Diverse Applications of Recombinant BCG-Based Vaccines to Target Infectious Diseases Other Than Tuberculosis: An Overview</article-title><source>Front. Microbiol.</source><year>2021</year><volume>12</volume><elocation-id>757858</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2021.757858</pub-id><pub-id pub-id-type="pmid">34745066</pub-id><pub-id pub-id-type="pmcid">PMC8566895</pub-id></element-citation></ref><ref id="B78-pathogens-12-01386"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bastos</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Borsuk</surname><given-names>S.</given-names></name><name name-style="western"><surname>Seixas</surname><given-names>F.K.</given-names></name><name name-style="western"><surname>Dellagostin</surname><given-names>O.A.</given-names></name></person-group><article-title>Recombinant Mycobacterium bovis BCG</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>6495</fpage><lpage>6503</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.08.044</pub-id><pub-id pub-id-type="pmid">19720367</pub-id></element-citation></ref><ref id="B79-pathogens-12-01386"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bastos</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Dellagostin</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Barletta</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Doster</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>E.</given-names></name><name name-style="western"><surname>Osorio</surname><given-names>F.A.</given-names></name></person-group><article-title>Construction and immunogenicity of recombinant Mycobacterium bovis BCG expressing GP5 and M protein of porcine reproductive respiratory syndrome virus</article-title><source>Vaccine</source><year>2002</year><volume>21</volume><fpage>21</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(02)00443-7</pub-id><pub-id pub-id-type="pmid">12443659</pub-id></element-citation></ref><ref id="B80-pathogens-12-01386"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanno</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Goulart</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rofatto</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Leite</surname><given-names>L.C.C.</given-names></name><name name-style="western"><surname>McFadden</surname><given-names>J.</given-names></name></person-group><article-title>New Recombinant Mycobacterium bovis BCG Expression Vectors: Improving Genetic Control over Mycobacterial Promoters</article-title><source>Appl. Environ. Microbiol.</source><year>2016</year><volume>82</volume><fpage>2240</fpage><lpage>2246</lpage><pub-id pub-id-type="doi">10.1128/AEM.03677-15</pub-id><pub-id pub-id-type="pmid">26850295</pub-id><pub-id pub-id-type="pmcid">PMC4959472</pub-id></element-citation></ref><ref id="B81-pathogens-12-01386"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Desel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dorhoi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bandermann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Grode</surname><given-names>L.</given-names></name><name name-style="western"><surname>Eisele</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kaufmann</surname><given-names>S.H.</given-names></name></person-group><article-title>Recombinant BCG DeltaureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses</article-title><source>J. Infect. Dis.</source><year>2011</year><volume>204</volume><fpage>1573</fpage><lpage>1584</lpage><pub-id pub-id-type="doi">10.1093/infdis/jir592</pub-id><pub-id pub-id-type="pmid">21933877</pub-id><pub-id pub-id-type="pmcid">PMC3192191</pub-id></element-citation></ref><ref id="B82-pathogens-12-01386"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nascimento</surname><given-names>I.P.</given-names></name><name name-style="western"><surname>Dias</surname><given-names>W.O.</given-names></name><name name-style="western"><surname>Mazzantini</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Miyaji</surname><given-names>E.N.</given-names></name><name name-style="western"><surname>Gamberini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Quintilio</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gebara</surname><given-names>V.C.</given-names></name><name name-style="western"><surname>Cardoso</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Raw</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Recombinant Mycobacterium bovis BCG expressing pertussis toxin subunit S1 induces protection against an intracerebral challenge with live Bordetella pertussis in mice</article-title><source>Infect. Immun.</source><year>2000</year><volume>68</volume><fpage>4877</fpage><lpage>4883</lpage><pub-id pub-id-type="doi">10.1128/IAI.68.9.4877-4883.2000</pub-id><pub-id pub-id-type="pmid">10948100</pub-id><pub-id pub-id-type="pmcid">PMC101688</pub-id></element-citation></ref><ref id="B83-pathogens-12-01386"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohara</surname><given-names>N.</given-names></name><name name-style="western"><surname>Matsuoka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nomaguchi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Naito</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>T.</given-names></name></person-group><article-title>Protective responses against experimental Mycobacterium leprae infection in mice induced by recombinant Bacillus Calmette-Guerin over-producing three putative protective antigen candidates</article-title><source>Vaccine</source><year>2001</year><volume>19</volume><fpage>1906</fpage><lpage>1910</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(00)00439-4</pub-id><pub-id pub-id-type="pmid">11228360</pub-id></element-citation></ref><ref id="B84-pathogens-12-01386"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soto</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Galvez</surname><given-names>N.M.S.</given-names></name><name name-style="western"><surname>Rivera</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Palavecino</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Cespedes</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Rey-Jurado</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bueno</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Kalergis</surname><given-names>A.M.</given-names></name></person-group><article-title>Recombinant BCG Vaccines Reduce Pneumovirus-Caused Airway Pathology by Inducing Protective Humoral Immunity</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>2875</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.02875</pub-id><pub-id pub-id-type="pmid">30581437</pub-id><pub-id pub-id-type="pmcid">PMC6293239</pub-id></element-citation></ref><ref id="B85-pathogens-12-01386"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bontempi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Leal</surname><given-names>K.</given-names></name><name name-style="western"><surname>Prochetto</surname><given-names>E.</given-names></name><name name-style="western"><surname>Diaz</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cabrera</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bortolotti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Morbidoni</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Borsuk</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dellagostin</surname><given-names>O.</given-names></name><name name-style="western"><surname>Marcipar</surname><given-names>I.</given-names></name></person-group><article-title>Recombinant Mycobacterium bovis BCG is a promising platform to develop vaccines against Trypansoma cruzi infection</article-title><source>Clin. Exp. Immunol.</source><year>2020</year><volume>201</volume><fpage>306</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1111/cei.13469</pub-id><pub-id pub-id-type="pmid">32464684</pub-id><pub-id pub-id-type="pmcid">PMC7419981</pub-id></element-citation></ref><ref id="B86-pathogens-12-01386"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mambelli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Marinho</surname><given-names>F.V.</given-names></name><name name-style="western"><surname>Andrade</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>de Araujo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Abuna</surname><given-names>R.P.F.</given-names></name><name name-style="western"><surname>Fabri</surname><given-names>V.M.R.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>B.P.O.</given-names></name><name name-style="western"><surname>da Silva</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>de Magalhaes</surname><given-names>M.T.Q.</given-names></name><name name-style="western"><surname>Homan</surname><given-names>E.J.</given-names></name><etal/></person-group><article-title>Recombinant Bacillus Calmette-Guerin Expressing SARS-CoV-2 Chimeric Protein Protects K18-hACE2 Mice against Viral Challenge</article-title><source>J. Immunol.</source><year>2023</year><volume>210</volume><fpage>1925</fpage><lpage>1937</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.2200731</pub-id><pub-id pub-id-type="pmid">37098890</pub-id><pub-id pub-id-type="pmcid">PMC10247535</pub-id></element-citation></ref><ref id="B87-pathogens-12-01386"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Queiroz</surname><given-names>N.</given-names></name><name name-style="western"><surname>Marinho</surname><given-names>F.V.</given-names></name><name name-style="western"><surname>de Araujo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fahel</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>S.C.</given-names></name></person-group><article-title>MyD88-dependent BCG immunotherapy reduces tumor and regulates tumor microenvironment in bladder cancer murine model</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><fpage>15648</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-95157-6</pub-id><pub-id pub-id-type="pmid">34341449</pub-id><pub-id pub-id-type="pmcid">PMC8329301</pub-id></element-citation></ref><ref id="B88-pathogens-12-01386"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Vaccination induces rapid protection against bacterial pneumonia via training alveolar macrophage in mice</article-title><source>eLife</source><year>2021</year><volume>10</volume><fpage>e69951</fpage><pub-id pub-id-type="doi">10.7554/eLife.69951</pub-id><pub-id pub-id-type="pmid">34544549</pub-id><pub-id pub-id-type="pmcid">PMC8455131</pub-id></element-citation></ref><ref id="B89-pathogens-12-01386"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Chaili</surname><given-names>S.</given-names></name><name name-style="western"><surname>Filler</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Solis</surname><given-names>N.V.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Diaz</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Yeaman</surname><given-names>M.R.</given-names></name></person-group><article-title>Innate Immune Memory Contributes to Host Defense against Recurrent Skin and Skin Structure Infections Caused by Methicillin-Resistant Staphylococcus aureus</article-title><source>Infect. Immun.</source><year>2017</year><volume>85</volume><fpage>e00876-16</fpage><pub-id pub-id-type="doi">10.1128/IAI.00876-16</pub-id><pub-id pub-id-type="pmid">27849182</pub-id><pub-id pub-id-type="pmcid">PMC5278165</pub-id></element-citation></ref><ref id="B90-pathogens-12-01386"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suen</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Moorlag</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>de Bree</surname><given-names>C.L.J.</given-names></name><name name-style="western"><surname>Koeken</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mourits</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Dijkstra</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lemmers</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bhat</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C.J.</given-names></name><etal/></person-group><article-title>BCG vaccination induces innate immune memory in gamma delta T cells in humans</article-title><source>J. Leukoc. Biol.</source><year>2023</year><elocation-id>qiad103</elocation-id><pub-id pub-id-type="doi">10.1093/jleuko/qiad103</pub-id><pub-id pub-id-type="pmid">37672677</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="pathogens-12-01386-f001" orientation="portrait"><label>Figure 1</label><caption><p>BCG-trained HSCs differentiate into monocytes and macrophages presenting epigenetic and metabolic rewirings. The BCG stimulates HSCs in the bone marrow (BM) microenvironment, inducing STAT1 and IFN-&#947; signaling. These pathways associated with epigenetic alterations in HSCs lay the foundation for BCG-induced central TI. The training of these cells is the explanation for long-term responses due to effector cells differentiated from HSCs, such as monocytes and macrophages, inheriting chromatin modifications and being prone to responding effectively upon unrelated infections. Differentiated cells also harbor metabolic changes, which help to maintain the epigenetic marks and immunologic enhancement. The understanding of mechanisms related to trained monocytes in blood represents the peripheral TI. [Signal transducer and activator of transcription 1 (STAT1), Interferon-gamma (IFN-&#947;), Histone 3 lysine 4 methylation (H3K4me3), Histone 3 lysine 27 acetylation (H3K27ac), <italic toggle="yes">Mammalian target of rapamycin complex 1</italic> (mTORC1)<italic toggle="yes">,</italic> and Tricarboxylic-acid (<italic toggle="yes">TCA</italic>)].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pathogens-12-01386-g001.jpg"/></fig><fig position="float" id="pathogens-12-01386-f002" orientation="portrait"><label>Figure 2</label><caption><p>Metabolic, epigenetic, and functional remodeling in BCG-trained macrophages are integrated into an interdependent circuit. The BCG induces metabolic and epigenetic alterations (left) that enable these phagocytes to perform functionally improved responses following stimulation (right). The metabolic shift includes enhancement of the PI3K/Akt/mTORC1 axis, which in turn orchestrates other changes in the metabolism, such as S6K phosphorylation, induction of glycolysis, and glutamine pathway. The last one has a key role in TCA-metabolite accumulation and epigenetic chromatin modifications. Furthermore, there is a higher NLRP3 expression in BCG-trained macrophages when compared to untrained counterparts. The possible crosstalk between mTOR and NLRP3 still needs to be demonstrated in BCG-mediated TI. All these cellular changes contribute to an improved response following a heterologous stimulus. Upon stimulation, these trained cells could exhibit increased expression of costimulatory molecules on the cell surface, inflammatory cytokine release, and inflammasome activation. The non-canonical and canonical inflammasome platforms could be enhanced in BCG-trained macrophages, contributing to IL-1&#946; secretion. (The interactions marked by the symbol&#8212;?&#8212;require formal elucidation). [Phosphoinositide-3-kinase (PI3K), <italic toggle="yes">Protein kinase B</italic> (Akt), Mammalian target of rapamycin (mTOR), Ribosomal protein S6 kinase (S6K), <italic toggle="yes">NOD-like receptor (NLR) family pyrin domain-containing 3</italic> (<italic toggle="yes">NLRP3</italic>)<italic toggle="yes">,</italic> Gasdermin D (GSDMD), <italic toggle="yes">Major histocompatibility complex</italic> class II (MHC-II), Cluster of differentiation (CD), Tumor necrosis factor &#945; (TNF-&#945;), and Interleukin (IL)].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pathogens-12-01386-g002.jpg"/></fig><fig position="float" id="pathogens-12-01386-f003" orientation="portrait"><label>Figure 3</label><caption><p>Conventional and trained immunity-based vaccine approaches. Schematic representation of (<bold>A</bold>) conventional vaccine and (<bold>B</bold>) trained immunity-based vaccine (TIbV) designs. (<bold>A</bold>) Conventional vaccines are designed to achieve T/B cell activation and specific long-term memory responses against a specific pathogen. (<bold>B</bold>) On the other hand, by making use of a TI inducer (PAMPs such as glucans or vaccines known to induce TI), TIbVs aim to stimulate the innate immune system (straight arrows). Epigenetic reprogramming and metabolism alterations will lead to (upon a secondary stimulus) an enhanced non-specific response orchestrated by the innate immune system. Moreover, this method can also be used to improve the adaptive immune response (dashed arrows) when the TI inducer is followed by a booster immunization with a specific antigen. The more responsive innate immune system will lead to an enhanced adaptive response, with elevated humoral responses, quicker serum conversion, and higher T/B cell proportions and functions.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pathogens-12-01386-g003.jpg"/></fig></floats-group></article></pmc-articleset>